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Abstract
Despite decades of research, tuberculosis remains the oldest pathogen-based disease that is the leading
cause of death from a single infectious agent. Among many anti-tubercular therapies under investigation,
the semisynthetic compounds spectinamides are a promising novel class of anti-tuberculosis agents.
One such lead candidate, spectinamide 1810, and backup spectinamide 1599 have demonstrated
excellent efficacy, safety, and drug-like properties in various in vitro and in vivo assessments. The doseranging and dose fractionation studies were designed to characterize the dose-exposure-response
relationship for lead and backup spectinamide in a mouse model of Mycobacterium tuberculosis
infection. In this current study, we used 26 and 23 combinations of dose level and dosing frequency for
the lead and backup spectinamide, respectively. The dedicated pharmacokinetic studies with a collection
of series of blood samples were conducted in healthy animals. Population pharmacokinetic analysis was
performed using non-linear mixed effect modeling to estimate pharmacokinetic parameters in healthy
animals. The Bayesian principles were applied for reliable pharmacokinetic estimation in infected animals
by using informed priors obtained from healthy animals. The individual pharmacokinetic parameters were
obtained for infected animals through post-hoc estimation and subsequently used for pharmacokinetic/pharmacodynamic (PK/PD) indices and mechanism-based PK/PD modeling.
The obtained data on spectinamides’ plasma concentrations and counts of colony-forming units were
analyzed using a PK/PD approach as well as classical anti-infective PK/PD indices. The population
pharmacokinetic analysis results suggest that there is no difference in the pharmacokinetic parameters
of lead and backup spectinamide in infected animals as compared to healthy animals. The PK/PD index
analysis showed that the efficacy of spectinamide 1810 is largely driven by concentration (Cmax/MIC)
and exposure (AUC/MIC) rather than a threshold minimum inhibitory level (T>MIC). Although similar
results were obtained for spectinamide 1599 in previously performed in vitro experiments, in the present
in vivo studies, spectinamide 1599 did not demonstrate the expected correlation between efficacy and
PK/PD indices. Therefore, we could not identify major drivers for the efficacy of this compound.
Additionally, a novel mechanism-based PK/PD model with consideration to post-antibiotic effect could
adequately describe the exposure-response relationship for lead and backup spectinamide. This supports
the idea that the in vitro observed post-antibiotic effect of these spectinamides can translate to the in vivo
situation, as well. Altogether we suggest, the obtained results and pharmacometric model for the
exposure-response relationship of lead and backup spectinamides provide a rational basis for dose
selection for future efficacy studies of these compounds against Mycobacterium tuberculosis in mice and
other animal species.
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ABSTRACT

Despite decades of research, tuberculosis remains the oldest pathogen-based
disease that is the leading cause of death from a single infectious agent. Among many
anti-tubercular therapies under investigation, the semisynthetic compounds spectinamides
are a promising novel class of anti-tuberculosis agents. One such lead candidate,
spectinamide 1810, and backup spectinamide 1599 have demonstrated excellent efficacy,
safety, and drug-like properties in various in vitro and in vivo assessments. The doseranging and dose fractionation studies were designed to characterize the dose-exposureresponse relationship for lead and backup spectinamide in a mouse model of
Mycobacterium tuberculosis infection. In this current study, we used 26 and 23
combinations of dose level and dosing frequency for the lead and backup spectinamide,
respectively. The dedicated pharmacokinetic studies with a collection of series of blood
samples were conducted in healthy animals. Population pharmacokinetic analysis was
performed using non-linear mixed effect modeling to estimate pharmacokinetic
parameters in healthy animals. The Bayesian principles were applied for reliable
pharmacokinetic estimation in infected animals by using informed priors obtained from
healthy animals. The individual pharmacokinetic parameters were obtained for infected
animals through post-hoc estimation and subsequently used for pharmacokinetic/pharmacodynamic (PK/PD) indices and mechanism-based PK/PD modeling.
The obtained data on spectinamides’ plasma concentrations and counts of colonyforming units were analyzed using a PK/PD approach as well as classical anti-infective
PK/PD indices. The population pharmacokinetic analysis results suggest that there is no
difference in the pharmacokinetic parameters of lead and backup spectinamide in infected
animals as compared to healthy animals. The PK/PD index analysis showed that the
efficacy of spectinamide 1810 is largely driven by concentration (Cmax/MIC) and
exposure (AUC/MIC) rather than a threshold minimum inhibitory level (T>MIC).
Although similar results were obtained for spectinamide 1599 in previously performed in
vitro experiments, in the present in vivo studies, spectinamide 1599 did not demonstrate
the expected correlation between efficacy and PK/PD indices. Therefore, we could not
identify major drivers for the efficacy of this compound. Additionally, a novel
mechanism-based PK/PD model with consideration to post-antibiotic effect could
adequately describe the exposure-response relationship for lead and backup spectinamide.
This supports the idea that the in vitro observed post-antibiotic effect of these
spectinamides can translate to the in vivo situation, as well. Altogether we suggest, the
obtained results and pharmacometric model for the exposure-response relationship of
lead and backup spectinamides provide a rational basis for dose selection for future
efficacy studies of these compounds against Mycobacterium tuberculosis in mice and
other animal species.
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CHAPTER 1.

INTRODUCTION

Tuberculosis
Tuberculosis (TB) is a global threat and the leading cause of death from a single
infectious agent. Mycobacterium tuberculosis (Mtb) is the causative agent of TB. As per
the recent reports of WHO, 10 million new cases of TB were reported, and 1.5 million
deaths occurred globally in 2018 [1]. The majority of the people infected with TB,
control the infection, and remain asymptomatic; commonly referred to as latent TB
infection (LTBI). It is estimated that about one-third of the world population has LTBI.
TB is a contagious infection and transmitted via air when a healthy person inhales
droplets containing Mtb, that is exhaled from actively infected TB patients. Ingested
droplets carrying bacilli, deposit in the alveolar space of the lungs where they are
phagocytosed by resident alveolar macrophages upon interaction with macrophage
surface receptors such as mannose and complement receptors [2, 3]. The infected
macrophages through the production of chemokines, recruit phagocytic cells including
monocytes, neutrophils, lymphocytes, dendritic cells, and other alveolar macrophages at
the site of infection and initiate granuloma formation. The variability in the recruited
population of phagocytic cells determines the fate and heterogeneity of granulomas in the
later stage of infection. A granuloma is a well-organized structure composed of trapped
bacilli surrounded by infected and non-infected macrophages, lymphocytes, fibroblasts,
and multinucleated giant cells [2, 4]. Despite the very effective immune response,
complete eradication of bacilli from the body is improbable and the bacilli remain
dormant. Active host immunity essentially plays an important role in the containment of
bacteria in a latent form. The dormant bacilli typically transform back to an active form
in a host with a compromised immune system, as a result of immunosuppressive
conditions or in a disease condition, such as AIDS (Acquired immunodeficiency
syndrome).

Standard of Care Treatment for TB
When the host’s immune system fails to stop the growth of TB bacteria, the
individual becomes sick and starts showing symptoms associated with active TB. At this
stage, patients must be treated promptly to; 1) rapidly reduce the number of fast-growing
bacteria, to prevent disease severity, mortality, and/or transmission of Mtb from an
infected to healthy individual 2) eradicate persisters, to prevent relapse 3) prevent the
acquisition of drug resistance.
An ideal treatment regimen for TB should be able to cure it permanently with
short treatment duration, prevent the emergence of resistant strains, and minimally harm
patients with other treatment-related side effects. However, the current standard of care
treatment consists of a combination of multiple agents administered for a long duration.
This is usually associated with severe side effects and sometimes leads to the
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development of resistance. TB is usually more prevalent in underdeveloped
socioeconomic countries so the return on investment would be lower for the development
of newer drugs for the treatment of TB. This unlucrative fact has discouraged leading
pharmaceutical industries to invest in TB portfolios. As a result of this, in the last four
decades, only two new drugs; bedaquiline and delamanid were clinically approved for the
treatment of TB.

Recommended Treatment for Drug Susceptible TB
For the newly diagnosed pulmonary TB patients, two phases of treatment are
recommended. In the intensive phase, treatment of isoniazid (INH), rifampin (RIF),
pyrazinamide (PZA), and ethambutol (EMB) is given for 2 months to achieve a rapid
decline in Mtb burden. The continuation phase consists of 4 to 7 months of treatment with
INH and RIF to accomplish complete sterilization. EMB can be excluded from the
intensive phase if the patient’s isolate is found to be susceptible to both INH and RIF. A
continuous effort by healthcare providers/researchers is taken to shorten the duration of
treatment. Multiple clinical trials have been conducted to test the safety and efficacy of
high dose RIF for shortening the duration of treatment [5-7]. The findings from all these
clinical trials clearly demonstrate the benefits of high dose RIF towards the shortening of
treatment duration. The highest tested dose of 35 mg/kg was well tolerated and provided
superior benefits as compared to 10 mg/kg, which is usually given in standard of care
treatment. In another study to shorten treatment duration, fluoroquinolones were either
added or substituted in the standard regimen to treat susceptible TB; however, they failed
to show any promising benefits [8, 9].

Recommended Treatment for Drug-Resistant TB
The cases of drug-resistant TB are categorized based on the resistance of Mtb to
certain drugs. Multiple drug resistance TB (MDR-TB) is defined as TB caused by
bacteria resistant to at least INH and RIF. Extensively drug resistance TB (XDR-TB) is
defined as TB caused by bacteria resistant to RIF, INH, fluoroquinolones and, at least one
of the three injectable second-line drugs (amikacin, kanamycin, or capreomycin). As per
the WHO guideline issued in 2011, recommended treatment for MDR-TB includes, at
least four and ideally five drugs which are likely to be effective against the MDR-TB
strain of Mtb and are given for at least 20 months duration [10]. Based on the strong
recommendation, the list of drugs to be included is a fluoroquinolone, ethionamide (or
protionamide) and as per the conditional recommendation, later generation
fluoroquinolones, injectable agents, PZA, and either cyclosporin or p-aminosalicylic acid
(PAS) are prescribed. EMB can be added but should not be counted among the four
effective drugs [10]. The inclusion of novel agents like bedaquiline and linezolid has
dramatically improved the treatment regimen for MDR and XDR-TB therapy and
reduced treatment duration from at least 24 months to 9-12 months.
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Spectinamides: A Potential New Treatment Against Drug-Resistant Tuberculosis
Spectinamides are semisynthetic analogs of natural antibiotic spectinomycin.
Spectinamides upon structure-based design offer manifold benefits over spectinomycin.
Despite being a potent protein synthesis inhibitor, spectinomycin exhibit poor activity
against Mtb. However, in contrast, spectinamides display an excellent anti-tubercular
activity by selectively inhibiting bacterial ribosome synthesis. A peculiar characteristic of
evading Rv1258c mediated efflux bestows spectinamides an edge over spectinomycin
and makes them immune to macrophage-induced drug tolerance that stems from the
upregulation of efflux pumps [11]. Along with the susceptible strains, spectinamides
retained activity against MDR and XDR-TB clinical isolates. Regarding pharmacokinetic
behavior, spectinamides have low plasma protein binding, excellent stability against
hepatic microsomal metabolism, and are eliminated predominantly by the renal route.
In a series of experiments, spectinamides were screened for in vivo efficacy in
multiple murine models challenged with Mtb. After the initial evaluation, spectinamides
demonstrated significant in vivo efficacy in reducing bacterial burden in lungs when
compared to controls in acute Mtb infection models [11]. Robertson et al have tested
spectinamide 1810 and spectinamide 1599 in Balb/c and C3HeB/FeJ mice both in acute
as well as chronic models; alone and in combination with existing frontline and novel
anti-TB agents. The findings from these studies showed that both spectinamide 1810 and
spectinamide 1599 are effective in significantly reducing the bacterial burden in all tested
murine models. Moreover, when paired with RIF, spectinamide 1599 proved highly
efficacious and demonstrated appreciable synergy [12].
Anti-bacterial activity of spectinamides is derived through their affinity to bind
the bacterial 30S ribosomal subunit and thereby inhibit translocation and subsequent
protein synthesis [13]. When combined with other protein synthesis inhibitors like RIF
(in vivo) and clarithromycin (in vitro), spectinamide 1599 potentiated the anti-tubercular
activity of partner drugs and that resulted in synergistic interaction [12, 14]. The potential
explanation of this synergistic interaction could be explained by pharmacodynamic
interaction as the combined drugs act on different targets involved in the process of
protein synthesis or spectinamides are killing the mycobacterial subpopulation which is
otherwise tolerant to the partner combination drugs. The interaction could also be
possible at the pharmacokinetic level in which spectinamides increase the intracellular
concentration of other drugs of combination therapy through inhibition of Rv1258c efflux
pumps. Spectinamides also showed a strong synergistic effect when combined with more
than one first-line anti-TB agents. The addition of either spectinamide 1810 or
spectinamide 1599 to the combination of RIF and PZA resulted in significant
improvement in the efficacy as compared to the combination and each first-line drug
alone [12]. The results from combination studies are encouraging and clearly demonstrate
the benefits of partnering spectinamide with existing first-line anti-TB agents for
improved therapeutic outcomes. Moreover, the ability to kill drug-resistant strains would
potentially fit spectinamide into the drug regimen designed for patients infected with
MDR or XDR TB strains
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In conclusion, considering all druggable properties, the spectinamide class of
drugs could potentially be a promising candidate in the fight against difficult to treat,
highly resistant TB strains and hence these compounds from a novel class of anti-TB
agents deserve further preclinical investigation before their advance into clinical
development.

Mouse Models in TB Research
Although humans are the natural host of Mtb, several surrogate animal models
have been successfully developed to study critical events like granuloma formation
involved in the disease progression of TB.
The mouse is a commonly used animal model in TB research due to its ease of
handling, low cost, availability of abundant immunological tools and reagents, and
availability of inbred, outbred, and transgenic strains. A number of ways could be used to
infect the animals; however, low inoculum aerosol is the preferred method because it
mimics the natural route of infection in humans [15]. Mice display immunological
response similar to humans however, the disease pathology is significantly different. In
most of the mouse models, bacilli reside intracellularly in contrast to humans, where
bacilli are typically located in extracellular caseous lesions [16]. Balb/c and C57BL/6
mice do not show the presence of caseating granuloma, a typical hallmark of TB in
humans, however, a study in C3HeB/FeJ mice infected with Mtb demonstrated necrotic
granulomas comparable to those observed in humans [17]. Despite striking differences in
pathology concerning granuloma formation, comparable outcomes of relative potencies
were seen upon low dose aerosol infection in both Balb/c and C3HeB/FeJ mouse models
when treated with RIF and rifapentine [18]. Likewise, De Groote et al have found drug
efficacy for combination of INH, PZA and RIF comparable when tested in Balb/c and
C57BL/6 mouse models [19]. Although mouse models are not able to produce
pathological response for TB identical to humans, they are widely utilized for initial
screening of anti-TB agents in preclinical development.
The other animal models commonly used in TB research are the guinea pig and
rabbit. Guinea pigs are highly susceptible to TB infection as compared to other animal
models. Guinea pigs after low dose aerosol infection of Mtb show remarkable similarities
to necrotic lesions when compared with human latent TB infection [20, 21]. In the
experiment on the investigational drug, R207910 in guinea pigs revealed that bacilli in
the persistent form of Mtb do not get exposed to the drug and hence absolute sterilization
could not be achieved. The rabbit model for TB mimics features specific to progressive
TB in humans such as the development of heterogenous lesions like cellular lesions,
necrotic lesions, and cavitary lesions [20, 22, 23]. Therefore, in several studies, the rabbit
model has been used specifically to study the penetration of anti-TB agents into different
types of tubercular lesions and to establish the relationship between target site exposure
and efficacy. Kjellsson et al have used a rabbit model to investigate differential
penetration kinetics of three first-line anti-TB agents; INH, RIF, PZA, and the most
efficacious second-line agent, moxifloxacin [24]. With the help of non-linear mixed
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effect modeling, the rate and extent of penetration were estimated. Among four agents,
moxifloxacin exhibited superior penetration ability to reach the target site by achieving
seven times higher AUC in comparison to plasma exposure.

Post-Antibiotic Effect
Post-antibiotic effect (PAE), a pharmacodynamic phenomenon experienced by
most if not all antibiotics; is a time for which bacterial growth is suppressed even after
the removal of antibiotics from the system. This delayed growth phenomenon was first
observed in the 1940s for penicillin against Pneumococcus and Streptococcus.
Nevertheless, it did not gain scientific attention until 1970. There are several in vitro
methods that are reported to determine PAE but due to the lack of a gold standard method
inconsistent results were seen across different laboratories [25-30]. The most widely used
method compares the regrowth kinetics of bacteria exposed to antibiotics against
untreated bacteria after the removal of antibiotics from the media. Various techniques are
employed including repeated washing, dilution, or drug inactivation by enzymes like
penicillinase for penicillin for the rapid removal of drugs from media. PAE is calculated
as a time difference between time required for viable bacteria exposed to an antibiotic to
increase by 1 Log above the count observed after immediate removal of antibiotic and
corresponding time required for unexposed control bacteria. Generally, antibiotics are
exposed for 2h at concentrations 5-10 times higher than the minimum inhibitory
concentration (MIC). Although PAE is a widely observed phenomenon, very little is
known about the underlying mechanism. The most commonly proposed explanations for
PAE are the persistence of antibiotic at the site of action or non-lethal damage of
essential components of the cellular machinery of the organism [31-33]. Nucleic acid
inhibitors like the macrolide antibiotics erythromycin and clindamycin show 2-3h PAE,
and it is postulated that PAE is the time required to diffuse from their ribosomal binding
sites [26, 34]. The longer PAE exhibited by aminoglycosides is attributed to the lengthier
revival process of ribosomal machinery after non-lethal damage caused by non-covalent
binding to the ribosomal subunit. A similar explanation can be applied for ribosomal
inhibitors spectinomycin and its novel semisynthetic analog spectinamides for
extraordinarily longer PAE showed against Mycobacterium bovis Bacillus CalmetteGuérin (BCG) [11]. PAE has also been studied in vivo in several animal models such as
thigh infection in neutropenic mice, meningitis in rabbits, endocarditis in rats, and
pneumonia in guinea pigs [35-38]. For the determination of PAE, regrowth kinetics is
followed once plasma or target site concentration falls below the MIC of antibacterial
agents against the infecting organism. Among these animal models, PAE values obtained
by the thigh infection neutropenic mouse model were more closely matching with PAE
values obtained by in vitro assays.
The design of the dosing regimen for antibacterial drugs is highly driven by
pharmacokinetic/pharmacodynamic (PK/PD) indices which suggest whether bacterial
killing is driven by concentration above MIC or the percentage of time in which drug
remains above the MIC. Along with PK/PD indices, PAE should also be considered
while deciding on selecting an optimal dosing regimen for antibacterial agents. An
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antibacterial agent with longer PAE would permit drug concentration to fall below MIC
without considerable alteration in efficacy. The longer PAE and concentration-depending
killing would be the most favorable pharmacodynamic characteristics for antibiotics such
as aminoglycosides to administer higher doses with lesser frequency for optimal efficacy,
patient compliance, and cost. In contrast, agents like penicillin which show timedependent killing and exhibit shorter PAE, need to be administered more frequently in
smaller doses.

Model-Based Dose Selection Strategies for Anti-Infective Agents
An optimal dosing regimen design is an indispensable component of a successful
drug development process. In the case of anti-infective agents, the right dose and right
dosing interval would lead to desirable pharmacological outcomes without causing
unwanted adverse effects and prohibiting the emergence of drug-resistant strains. Several
model-based approaches have been utilized in guiding the dose-finding process for antiinfective agents. Traditionally, pharmacodynamic indices are used to determine the
driving factors for efficacy. In the evaluation of PK/PD indices, exposure in terms of
maximum concentration (Cmax) of drug or area under the concentration-time curve (AUC)
above MIC or time for which drug remains above MIC are related to efficacy parameters.
The relationship between PK/PD indices and efficacy could then be helpful to design the
dosing regimen such as how much and how frequently anti-infective agents should be
administered to achieve the best efficacy. As per the modern approaches, mechanismbased PK/PD modeling is extensively employed to establish the exposure-response
relationship, which successively helps in making model informed decisions for the
selection of optimal dosing regimens. The input of PK parameters is required for both
evaluation of PK/PD indices and exposure-response assessment, and typically PK
parameters are estimated using population PK analysis.
In this section, the various components such as population PK analysis, PK/PD
indices, and mechanism-based PK/PD modeling involved in model informed dose
selection for anti-infective agents will be discussed elaborately.

Population Pharmacokinetic Analysis
The pharmacokinetic analysis is a mathematical curve fitting method to estimate
various constants known as PK parameters that determine the shape of the concentrationtime curve obtained after administration of a specific dose in animal or human subjects.
Typically for one-compartment IV bolus, these constants are clearance and volume of
distribution; the absorption rate constant will be an additional constant if the drug is
administered orally. To study the PK behavior of investigational drugs, several subjects
will be dosed with a range of dose levels. The population PK analysis approach is
employed in such cases to estimate PK parameters. In the study population, not every
individual behaves identically, oftentimes administration of the same dose results in
different concentrations in a different individual. Numerous factors can be responsible for
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the introduction of the observed variability in concentration-time profiles among the
study population. Based on the source, the variability component is classified into two
types. The first component of variability is known as between-subject variability and it is
originated from the intrinsic factors which are specific to study subjects; such as, body
weight, organ function, and extrinsic factors like the effect of food consumption and
administration of concomitant medication. This component of variability can easily be
explained through covariate analysis which quantitatively defines the effect of these
intrinsic and extrinsic factors on PK parameters which govern the systemic exposure of
any given drug. The covariate analysis is an integral part of population PK analysis when
it comes to adjustment of dose for specific subpopulations classified based on
demographic characteristics. The second component of variability is called
random/residual unexplained variability. The sources responsible for this component of
variability are unknown and hence this variability cannot be explained.
The Population PK model building process consists of the following steps:
Base model development
The base model consists of an appropriate structural model based on the PK
behavior of the drug; such as a one or two-compartment model with the specification for
between subject and random residual variability. Although there are multiple ways to
specify between-subject variability, the use of an exponential function as shown in
Equation 1-1 to keep PK parameters on the positive side is recommended.
𝑃𝑖 = 𝑃𝑝𝑜𝑝 × 𝑒 𝜂𝑖

Eq. 1-1

Where, 𝑃𝑖 is the parameter estimate for subject i, 𝑃𝑝𝑜𝑝 represents the typical
population value for the parameter, and ηi is the independent random variable in subject i,
described by a normal distribution with mean zero and variance ω2 , which corresponds to
a log-normal distribution for the parameter.
Residual random variability can be captured by one of the multiple error models
such as additive, proportional, exponential, or combinations of additive with either
proportional or exponential error models [39]. An example of an additive type of error is
shown in Equation 1-2.
𝐶𝑖𝑗 = Ĉ𝑖𝑗 + 𝜀𝑖𝑗

Eq. 1-2

Where, 𝐶𝑖𝑗 is the jth observed concentration in 𝑖 th subject, Ĉ𝑖𝑗 is the model
predicted concentration for the jth observation in 𝑖 th subject, and εij is the residual error
characterized by a normal distribution with mean zero and variance σ2 .
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Final model development
The final model is a base model with incorporation of biologically,
physiologically, pharmacologically, or clinically relevant covariates which significantly
explain between-subject variability. There are two commonly used approaches for
inclusion and evaluation of covariates. First, full model estimation in which predefined
covariates are included and the rationale for retaining a particular covariate is based on
the confidence interval around the parameter estimate. Another approach commonly
referred to as stepwise covariate modeling includes the stepwise addition of significant
covariates followed by backward elimination of insignificant covariates [40, 41].
Covariates can be binary (e.g. patients sex), categorical (e.g. ethnicity,) or continuous
(e.g. body weight). A variety of functions including linear (Equation 1-3) or power
(Equation 1-4) functions can be applied to introduce the covariate effect.
Linear function:
𝑃𝑖 = (𝑃𝑝𝑜𝑝 + (𝑊𝑇𝑖) ∗ 𝑃𝑐𝑜𝑣 ) × 𝑒 𝜂𝑖

Eq. 1-3

Power function:
𝑊𝑇𝑖 𝑃𝑐𝑜𝑣

𝑃𝑖 = 𝑃𝑝𝑜𝑝 + (

70

)

× 𝑒 𝜂𝑖

Eq. 1-4

Where, 𝑃𝑖 is the parameter estimate for subject i, 𝑃𝑝𝑜𝑝 represents the typical
population value for the parameter, 𝑃𝑝𝑜𝑝 represents the covariate effect value for the
parameter, In the power function, weight is normalized to mean or median value (70) for
the study population, WT is the weight of subject i , and ηi is the independent random
variable in subject i, described by a normal distribution with mean zero and variance ω2 ,
which corresponds to a log-normal distribution for the parameter.
Model evaluation and validation
In the early stages of model development, models are screened against multiple
aspects of model evaluation. An objective function is one of the most commonly used
factors to discriminate models and decide the best among all possible options. Graphical
evaluation of goodness of fit plots such as observed vs. predicted values, the spread of
residuals (weighted and conditional weighted) across time and predicted values is another
way to evaluate model performance in terms of agreement of predicted values to the
observed data. Simulation-based methods are usually employed in the later stages when
few candidate models are shortlisted. The visual predictive check (VPC) is one of the
methods in which simulations using selected model parameters and original database
design are performed to generate new data sets. Based on the simulated concentrationtime profile, typically 95% prediction intervals are created and compared with observed
values. Based on study design and sampling scheme; and for better graphical
representation, numerous approaches such as prediction corrected VPC (pVPC),
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standardized VPC (sVPC), and VPC by regression approach have been utilized for model
diagnosis [42-45]. The bootstrap analysis is a rigorous and time-consuming diagnostic
method mostly reserved for the final model. In the bootstrap analysis, typically 1000
replicates are selected to have a true representation of the distribution of the original
dataset and are evaluated using the final model. The resulting parameter distribution and
usually 95% confidence interval for each parameter are reported. The narrower and
symmetrical the distribution around the median is, the better is the precision of parameter
estimates.
One of the most important applications of population PK modeling is to obtain
individual PK parameters by post hoc estimation. In the case of PK/PD evaluation of
anti-infectives, PK parameters obtained for each individual are utilized to determine
PK/PD indices and also serve as PK input for sequential PK/PD modeling to characterize
exposure-response analysis.

PK/PD Indices
MIC is an in vitro potency determinant for anti-infectives, which seldomly proves
to be a successful predictor of clinical outcomes. In vitro methods such as disk diffusion,
E-test and microdilution have been used to determine MIC, a minimum static
concentration required to inhibit the growth of study bacteria [46]. However, in vivo drug
concentration is determined by PK parameters and it changes with time. MIC does not
provide the information about the time course of the anti-microbial effect nor the effect of
varying exposure of anti-infectives on bacterial kill rate. PK/PD indices evaluation is an
approach to integrate PK information with in vitro potency, which would be a more
accurate way to achieve better predictability.
Historically, the only aim of dose selection for an anti-bacterial agent was to
maintain plasma concentration above MIC throughout the treatment duration. However,
in the recent past, animal experiments with dose fractionation study designs provided
more informed insights into a better understanding of the PK/PD relationship of antibacterial agents [47-50]. In dose fractionation studies, a fixed daily/weekly dose is
administered as a single dose or fractionated into smaller doses and given with different
dosing frequencies. Based on these studies PK/PD indices including maximum drug
concentration above MIC (Cmax/MIC), area under the concentration-time curve over MIC
(AUC/MIC), and the cumulative percentage of time when drug concentration remains
above MIC (%T above MIC) are evaluated. After evaluation for PK/PD indices, antiinfective agents are categorized as antimicrobials with either concentration- or exposuredependent killing or antimicrobials with time-dependent killing.
Anti-infective agents with concentration- or exposure-dependent killing
Examples of anti-infective agents for which bacterial killing is mainly driven
either by Cmax or AUC above MIC are aminoglycoside, fluoroquinolones, vancomycin,
metronidazole, RIF, tetracyclines, linezolid [51-58]. For anti-infective agents in this
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category, it is irrational to just maintain concentration above MIC; rather, it is needed to
achieve maximum concentration and exposure permissible within the safety margin
above MIC, to gain a desired therapeutic response. Hence, a higher daily dose is
recommended over a smaller number of doses given frequently to obtain better clinical
outcomes. In severely ill patients suffering from pneumonia when treated with
intravenous ciprofloxacin with a dosage ranging from 200 mg Q12 and 400 mg Q8, was
found to have AUC/MIC ≥ 125 that resulted in favorable clinical outcome [59]. In the
case of aminoglycosides, gentamicin, and tobramycin Cmax/MIC ≥ 8 to 10 was
established as a pharmacodynamic target to achieve clinical response for treating patients
for sepsis and nosocomial pneumonia [60, 61].
Anti-infective agents with time-dependent killing
β-lactam antibiotics are classical examples of anti-infective agents exhibiting
time-dependent killing and in this case, the amount of time drug remains above MIC is a
predictor for efficacy. Therefore, frequent smaller doses would be sufficient to maintain
concentration above MIC and to achieve desirable efficacy as compared to higher doses
given less frequently. Based on a study conducted in critically ill patients it is
recommended for β-lactams, cephalosporins, and carbapenems that concentrations above
4 × MIC should be maintained during 40-70% of the dosing interval and set as the most
conservative PK/PD target [62]. In the case of cefepime, it was observed in patients
infected with Pseudomonas aeruginosa that unbound concentrations maintained above
the MIC for > 60% of dosing interval would minimize the chances of poor
microbiological response [63].

Mechanism-Based PK/PD Modeling
The traditional PK/PD modeling-based approaches are oftentimes used in the drug
development process to build the quantitative relationship between exposure and
response. Well validated models with adequate predictive ability are then employed to
find the optimal dose that is expected to result in desired efficacy and safety outcomes.
Lately, mechanism-based approaches with the inclusion of drug-specific parameters and
biological system-specific parameters in the model building process have been used more
frequently to enhance model performance and predictive ability [64]. The drug-specific
parameters include target site distribution, target occupancy, and biological systemspecific parameters such as target expression level. The rate constant of processes
governing target turnover provides more detailed information about drug and biological
systems that helps in establishing a stronger relationship between exposure and efficacy.
Mechanism-based PK/PD models typically applied to characterize antibacterial
drug effects include bacterial cell growth and cell kill functions to describe natural
growth kinetics of bacteria and drug effect is applied as inhibitory and/or stimulatory
function on cell growth and/or kill functions respectively.
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Typically, in the mechanism-based PK/PD model, growth kinetics of bacteria in
control groups are described by linear capacity-limited functions such as first-order rate
constant, logistic growth expression, or non-linear growth velocity (VGmax) limited
function. Another approach particularly applied for subpopulation models in which
capacity growth function accounts for both growth of growing bacteria and its transfer
into resting/non-growing/dormant form of bacteria. To input the concentration
component into the PK/PD model, the population PK model is developed to describe the
time course of concentration after administration of a defined dosing regimen.
Subsequently, models describing the time course of bacterial burden and concentration of
antibacterial agents will be integrated to build an integrated mechanism-based PK/PD
model by applying drug effect either as inhibition of growth and/or stimulation of death
of bacteria through one of the pharmacodynamic models such as linear, Emax or sigmoidal
Emax–model to characterize the exposure-response relationship. Table 1-1 lists some of
the examples of mechanism-based PK/PD models published to study the effect of
antibacterial agents on the reduction of bacterial burden.
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Table 1-1.

Examples of mechanism-based PK/PD models available for antibacterial agents

Test bacteria

Number of
bacterial
population

Bacterial growth
function

Drug/s

Pseudomonas
aeruginosa

One

Meropenem

Mycobacterium bovis

One

INH
Benzylpenicillin,
Cefuroxime,
Erythromycin,
Moxifloxacin, and
Vancomycin
Ciprofloxacin
Levofloxacin

Streptococcus
pyogenes

Two

Staphylococcus
aureus

Two

Escherichia
coli

Two

Ciprofloxacin

Pseudomonas
aeruginosa

Two

Combination ImipenemRelebactam

Mycobacterium
tuberculosis

Three

RIF

Reference

Linear with logistic
function
Linear with logistic
function

Stimulatory sigmoidal
Emax on death rate
Stimulatory sigmoidal
Emax on death rate

Linear with firstorder rate constant

Stimulatory sigmoidal
Emax on death rate

[67]

Linear with logistic
function
Non-linear with
Vmax (maximum
velocity) function
Linear with logistic
function

Stimulatory sigmoidal
Emax on death rate

[68, 69]

Stimulatory sigmoidal
Emax on death rate

[70]

Linear with first
order rate constant
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Drug effect

Stimulatory sigmoidal
Emax on death rate
Inhibitory Emax on growth
rate and stimulatory
sigmoidal Emax on death
rate

[65]
[66]

[71]

[72]

CHAPTER 2.

SPECIFIC AIMS

TB is an infectious disease caused by Mycobacterium tuberculosis (Mtb) causing
over 1.5 million fatalities annually, accounting for substantially more than any other
infectious disease [1, 73]. Treatment of TB to date remains cumbersome due to prolonged
duration, severe side effects, and increased complexity by an order of magnitude due to
the emergence of MDR and XDR TB strains [74]. Spectinamides are novel semisynthetic
analogs of spectinomycin with potent anti-TB activity. In multiple murine models,
spectinamides have proven to be efficacious and well-tolerated. In vitro spectinamides
were found highly active against MDR and XDR Mtb [11]. Recently, spectinamide 1810
was nominated as a lead candidate, and spectinamide 1599 as a backup compound, due to
their excellent pharmacological properties and safety profiles [13, 75]. Owing to these
favorable properties, we selected these two spectinamides for the scope of our
investigation.
Mechanism-based PK/PD modeling and simulation tools have been widely used
for the selection of efficacious dosing regimens during the development process of
antibacterial agents [76]. In pre-clinical development, typical animal studies are
conducted in rodent infection models administered with a range of dose levels and dosing
frequencies, followed by efficacy measurement in terms of reduction of colony-forming
units (CFU) relative to control (untreated). CFU is a quantitative measure of bacterial
burden in the infected tissues. While integrating the exposure of antibacterial agents with
its putative effect in target tissues, it is a prerequisite to characterize the natural growth
kinetics of bacteria in the target tissues. Several PK/PD modeling approaches have been
used to explore the bacterial-kill kinetics of anti-TB drugs including one- and, twopopulation models that differentiate the effect on fast and dormant/slow-growing
bacteria, as well as multistate models with fast, slow, and non-growing states [67, 77].
The model selection has largely been driven by bacterial physiology as well as the
availability of sufficient in-vitro data to support the estimation of the differential growth
kinetics of various subpopulations.
Additionally, a large number of publications in the field of anti-bacterial
pharmacotherapy is focused on the evaluation of PK/PD indices [57, 78]. PK/PD indices
are frequently used to identify the major PK drivers for antibacterial efficacy, as a
guidance for clinical dose optimization. Typically, dose fractionation studies are
conducted in vivo by administration of smaller fractions of doses with varying dosing
frequency and multiple total daily dose levels. Based on these studies, the exposureresponse relationship for the PK/PD indices such as Cmax/MIC, AUC/MIC, and %T above
MIC are determined. The relationship between PK/PD indices and the response is a
benchmark for determining the reduction in bacterial burden, which suggests the potential
of the antibacterial agent to exhibit either concentration-, exposure- or time-dependent
killing. Aminoglycoside and fluoroquinolone antibiotics show concentration- or
exposure-dependent killing, whereas β-lactam antibiotics show time-dependent killing
[79-81]. With anti-TB drugs such as RIF and INH efficacy is mainly Cmax and AUC
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driven, whereas pretomanid exhibits time-dependent activity in murine TB models [8284].
Another interesting antibacterial pharmacotherapy measurable attribute is the
determination of the PAE, which is a residual antibacterial activity which endures beyond
the removal of antibacterial agent from the system. The plausible mechanisms leading to
PAE are, delayed recovery after reversible, non-lethal damage to cell structures,
prolonged persistence of the drug at a binding site or within the subcellular target space,
or the need for the bacteria to synthesize new enzymes or other essential molecules in a
time-consuming process before initiation of regrowth [85-87]. A variety of antibacterial
agents including aminoglycosides, β‐lactams, INH, RIF, and PZA were reported to
exhibit PAE [88-90]. Spectinamides also exhibit substantial PAE in vitro, 20h for
spectinamide 1810, and 133h for spectinamide 1599 against Mycobacterium bovis at 10x
MIC [13]. Several researchers investigated PAE as an in vitro phenomenon, while only a
modest number of in vivo studies were evaluated to date, despite the postulated PAE
mechanisms suggesting that PAE can very well be expected in vivo. To the best of our
knowledge, modeling and simulation tools have not yet been explored for the estimation
of PAE in-vivo.
Spectinamide 1810 and spectinamide 1599 were tested in vivo for efficacy against
Mtb in a low dose aerosol infection mouse model of TB. The range of dose levels and
dosing frequency were selected to potentially achieve a wide range of exposure leading to
corresponding response. The central hypothesis was spectinamides under investigation
follow a defined dose-exposure-response relationship in their efficacy against Mtb. To
support our hypothesis, we have designed the following specific aims and would explore
a variety of quantitative and pharmacometrics-driven PK/PD modeling and simulation
tools to investigate these specified aims.

Specific Aim 1
Population PK analysis is utilized to estimate PK parameters for the given
population and as well as for each individual in the population by post-hoc estimation. To
obtain the drug exposure in each infected animal in the dose-ranging and dose
fractionation study, we performed a population PK analysis. The practical limitations
imposed the collection of serial blood samples from infected animals, which would
hinder the reliable PK parameter estimation. To address this issue, a dedicated single and
multiple-dose PK studies in healthy animals which allowed the collection of a series of
blood samples were performed. Population PK analysis was performed on intensive data
obtained from healthy animals and subsequently used for PK analysis in infected animals.
In specific aim 1 (Chapter 4), it was hypothesized that TB infection does not affect the
PK behavior of lead and backup spectinamide in Balb/c mice. Furthermore, PK
parameters were anticipated to be similar in healthy and infected animals. In order to
prove this hypothesis, we explored population PK analysis approaches to estimate PK
parameters in both healthy and infected animals.
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Specific Aim 2
For antibacterial agents, exposure parameters responsible for efficacy are
identified in early pre-clinical development. These are referred as PK/PD indices and are
evaluated based on in vitro time-kill experiments and/or in vivo dose-ranging and dose
fractionation studies. Previously, spectinamide 1599 was evaluated in in vitro time-kill
experiments and its anti-mycobacterial activity was best described by Cmax/MIC and
AUC/MIC [91]. Based on prior in vitro knowledge it was hypothesized (Chapter 5) that
spectinamides under investigation in the current in vivo dose-ranging and dose fraction
study would potentially behave similarly and exhibit Cmax/MIC and AUC/MIC driven
efficacy. In order to test this hypothesis, data obtained from in vivo studies was analyzed
to identify the major exposure drivers for efficacy.

Specific Aim 3
To establish a dose-exposure-response relationship, several PK/PD model-based
approaches are utilized to estimate drug derived parameters and characterize the doseexposure-response relationship. The lead and backup spectinamide were hypothesized to
follow a defined dose-exposure-response relationship for the efficacy against Mtb
(Chapter 6). Spectinamides in vitro demonstrated a high PAE and were hypothesized to
be observed in vivo as well. Therefore, it is important to integrate the PAE component in
the mechanism-based PK/PD modeling framework. To test the hypothesis, we developed
a mechanism-based PK/PD model with consideration of PAE to characterize the doseexposure-response relationship for lead and backup spectinamide on the data obtained
from dose-ranging and dose fractionation studied.
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CHAPTER 3.

ANIMAL EXPERIMENTATION, BIOANALYSIS, AND
MICROBIOLOGICAL ANALYSIS

Introduction
Animal studies were performed to generate an essential set of data required for
the comprehensive characterization of PK and PD behavior of spectinamides. Multiple
studies on Balb/c mice including healthy animal studies for PK analysis, and doseranging and dose fractionations studies in the standard and validated Mtb infected mouse
model for characterization of an exposure-response relationship were conducted at two
different sites; The University of Tennessee Health Science Center and Colorado State
University following the guidelines and approval from the Institutional Animal Care and
Use Committees of the respective institutions.

Chemical and Reagents
Spectinamide 1810 (2-(5-hydroxypyridin-2-yl)-N((2R,4R,4aS,5aR,6S,7S,8R,9S,9aR,10aS) -4a,7,9-trihydroxy-2-methyl-6,8bis(methylamino)decahydro-2H-benzo[b]pyrano[2,3-e][1,4]dioxin-4-yl)acetamide),
Spectinamide 1599 (2-(5-chloroypyridin-2-yl)-N((2R,4R,4aS,5aR,6S,7S,8R,9S,9aR,10aS) -4a,7,9-trihydroxy-2-methyl-6,8bis(methylamino)decahydro-2H-benzo[b]pyrano[2,3-e][1,4]dioxin-4-yl)acetamide) and
internal standard (3′-dihydro-3′-deoxy-3′(R)-isopropylacetylamino spectinomycin) were
synthesized in Dr. Richard E. Lee’s laboratory at St. Jude Children’s Research Hospital,
Memphis, TN as previously described [13]. Acetonitrile, methanol, HPLC grade water,
formic acid and nonafluoropentanoic were purchased from Fisher Scientific (Pittsburgh,
PA).

Healthy Animal Studies
Single and multiple-dose studies for the PK analysis of spectinamides in healthy
mice were performed at the University of Tennessee Health Science Center following
approval by the local Institutional Animal Care and Use Committee. Spectinamides were
evaluated for PK analysis after subcutaneous (SC) administration.

Mice
Female Balb/c mice, 8 weeks, weighing 18-22 g were purchased from Charles
River Laboratories (CA, USA) and acclimatized for a 72 h light/ dark cycle with access
to food and water ad libitum.
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Dosing Procedure
Formulations of spectinamides were prepared with varying proportions of water
and PlasmaLyte A for each group to maintain ideal osmotolerance close to physiological
values. All solutions were filtered through a 0.22 μm filter (MILLEX-GP, Millipore PES
membrane, cat #SLGP033RB). Dosing solutions were prepared based on the average
mouse body weight and a fixed volume of 50 µL was administered into each mouse via
SC route on each occasion. Various dosing schemes evaluated by SC administration are
specified in Table 3-1.

Sampling Procedure
Groups of three mice were sacrificed at predefined time points post-dose and
blood samples were obtained by cardiac puncture under isoflurane anesthesia followed by
euthanasia. For single-dose studies, samples were collected at 0.083, 0.25, 0.5, 1, 3, 8,
and 24h, and for multiple-dose studies at pre-dose, 0.083, 0.25, 1, 3, and 8h after
administration of the last dose. Plasma was immediately separated by centrifugation
(6,000×g for 10 min at 4°C) and stored at -70°C until analysis.

The Dose-Ranging and Dose Fractionation Studies in Mtb-Infected Mice
The dose-ranging and dose fractionation studies with PK and efficacy assessments
were conducted in a dedicated BSL-3 facility at Colorado State University according to
the guidelines of the Colorado State University Institutional Animal Care and Use
Committee under the direction of Dr. Anne Lenaerts and Dr. Gregory Robertson. Figure
3-1 depicts a schematic representation of the overall study design.

Mice
Six to eight-week-old Balb/c female mice were ordered from Charles River
Laboratories. Mice were infected 1-3 weeks after they arrived at CSU.

Experimental Protocol
Mice were infected with Mtb Erdman in the standard manner with a low dose
aerosol infection as previously described, using an inoculum concentration of 2.0×106
CFU/mL to achieve deposition of ~100 CFU in the lungs [92]. Spectinamides were
formulated in Plasma-Lyte (Baxter, Deerfield, IL) and water with different ratios for each
group to maintain ideal osmotolerance close to physiological values, and 0.2 ml of the
formulation was administered subcutaneously using a 29 gauge insulin syringe. In the
studies conducted on spectinamide 1810, at day 34 post-infection, SC administration was
initiated for groups of 5 mice in study 1A and 6 mice in study 1B with dosing regimens
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Table 3-1.

Single and multiple SC dosing regimen in healthy Balb/c mice

Dosing frequency
SD
5x per week
(m-f)
SD
5x per week
(m-f)
3x per week
(m,w,f)
2x per week
(m,r)

Total weekly dose (mg/kg)
50 200 250 400 600 1000
Spectinamide 1810
50 200
SD SD
50
200
QD5
QD5
Spectinamide 1599
50
SD
200
QD5
200
TIW
200
BIW

SD – once daily, single dose; QD5 – once daily for 5 consecutive days; m-f: Monday to
Friday; TIW – thrice weekly on Monday, Wednesday and Friday; BIW – twice weekly
on Monday and Thursday

Figure 3-1. Schematic representation of dose fractionation and dose-ranging
study of spectinamides conducted in Mtb infected female Balb/c mice
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as described in Tables 3-2 and 3-3 and continued for 4 weeks with drug holidays on
weekends (i.e., five days of consecutive dosing per week). Similarly, at day 34, 56, or 59
spectinamide 1599 was administered in groups of 5, 6, and 6 mice in study 2A, 2B, and
2C respectively with the dosing regimen described in Tables 3-4 and 3-5. For
practicability, the assessments were performed separately for each study for respective
spectinamide drug candidates. In total, 26 and 23 dose groups were administered for
spectinamide 1810 and spectinamide 1599, respectively, ranging from total daily doses of
20 mg/kg to 800 mg/kg and total weekly dose from 20 mg/kg to 4,000 mg/kg for
spectinamide 1810 and total daily doses of 2 mg/kg to 400 mg/kg and total weekly dose
from 10 mg/kg to 2,000 mg/kg for spectinamide 1599. Dosing frequencies ranged from
once per week (QW) over twice (TIW) and thrice (TIW) per week to daily (QD) and
twice daily (BID) administrations. Two blood samples per mice were collected by
submandibular bleed collected in BD Microtainer plasma separator tubes containing
lithium-heparin (BD, Franklin Lakes, NJ): one at 0.25h and another at the 8h postadministration during the last week of dosing. Plasma was separated immediately by
centrifugation (~3750xg for 10 min at 4°C) and stored at -70°C until LC-MS/MS
analysis.

Bioanalysis

Correction for Radiation-Induced Analyte Loss
To allow quantification of spectinamides in the plasma specimens obtained from
infected animals outside of the BSL-3 laboratory, samples were sterilized by exposure to
gamma irradiation (approx. 1 MRad) according to a validated protocol. To account for
potential partial degradation of the analyte by irradiation, quality control samples with
known concentrations of an analyte (high, medium, low) were evenly placed among test
samples during sterilization and used to correct any loss of analyte in the plasma
specimens collected from the infected animals.

Sample Preparation
Sample preparation was performed by protein precipitation using methanol.
Plasma proteins were precipitated by the addition of 4-volumes (100 µL) of IS, 1329 (10
ng/mL) in methanol to a volume (25 µL) of plasma test sample. Samples were vortexed
(Fisher Scientific, USA) for 30 sec and centrifuged at 10,000×g for 10 min at 4°C and the
supernatants were collected for LC-MS/MS analysis.
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Table 3-2.

Dosing regimens evaluated for spectinamide 1810 in the dose-fractionation study (in terms of total weekly dose)

Dosing
frequency
5x per week
(m-f) twice
5x per week
(m-f)
3x per week
(m,w,f)
2x per week
(m,r)
1x per week
(m)
5x per week
(m-f) twice
5x per week
(m-f)
3x per week
(m,w,f)

Total weekly dose (mg/kg)
200 300 400 500 600 1000 1200 2000 3000 4000
Study 1A
10
20
50
100
200 300 400
BID
BID
BID
BID
BID BID BID
20
40
100
200
400
QD
QD
QD
QD
QD
20
40
100
200
400
TIW
TIW
TIW
TIW
TIW
20
40
100
200
BIW
BIW
BIW
BIW
20
40
100
QW QW
QW
Study 1B
50
200
BID
BID
100
QD
166
333
TIW
TIW
20

40

60

80

100

120

BID- Twice daily for 5 consecutive days; m-f: Monday to Friday; QD- Once daily for 5 consecutive days; m-f: Monday to Friday;
TIW - Thrice weekly on Monday, Wednesday and Friday; BIW - Twice weekly on Monday and Thursday; QW- Once weekly on
Monday
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Table 3-3.

Dosing regimens evaluated for spectinamide 1810 in the dose-fractionation study (in terms of total daily dose)

Dosing frequency
5x per week
(m-f) twice
5x per week
(m-f)
3x per week
(m,w,f)
2x per week
(m,r)
1x per week
(m)

40

100

10 BID

20 BID

50 BID

100 BID

200 BID 300 BID 400 BID

20 QD

40 QD

100 QD

200 QD

400 QD

20 TIW 40 TIW 100 TIW

200 TIW

400 TIW

20 BIW 40 BIW 100 BIW

200 BIW

20 QW

40 QW

166

Daily dose (mg/kg)
200
333
Study 1A

20

400

600

800

100 QW
Study 1B

5x per week
(m-f) twice
5x per week
(m-f)
3x per week
(m,w,f)

50 BID

200 BID

100 QD
166 TIW

333 TIW

BID- Twice daily for 5 consecutive days; m-f: Monday to Friday; QD- Once daily for 5 consecutive days; m-f: Monday to Friday;
TIW - Thrice weekly on Monday, Wednesday and Friday; BIW - Twice weekly on Monday and Thursday; QW- Once weekly on
Monday
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Table 3-4.

Dosing regimens evaluated for spectinamide 1599 in the dose-fractionation study (in terms of total weekly dose)

Dosing frequency

10

20

30

40

50

Total weekly dose (mg/kg)
80 120 166 200 300

500

1000 1600 2000

50
BID
100
QD

100
BID
200
QD

Study 2A
5x per week
(m-f) twice
5x per week
(m-f)
3x per week
(m,w,f)
2x per week
(m,r)
1x per week
(m)

1
BID
2
QD

5
BID
10
QD

20
BID
40
QD

10
TIW

40
TIW

10
BIW
10
QW

200
BID

99.6
TIW

40
BIW
40
QW
Study 2B

5x per week
(m-f) twice
3x per week
(m,w,f)
2x per week
(m,r)
1x per week
(m)

100
BID
66
TIW
100
BIW

166
BID

166
TIW

166
QW
Study 2C

5x per week
(m-f) twice
5x per week
(m-f)
3x per week
(m,w,f)
2x per week
(m,r)

50
BID
100
QD
166
TIW
100
BIW

BID- Twice daily for 5 consecutive days; m-f: Monday to Friday; QD- Once daily for 5 consecutive days; m-f: Monday to Friday; TIW - Thrice
weekly on Monday, Wednesday and Friday; BIW - Twice weekly on Monday and Thursday; QW- Once weekly on Monday
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Table 3-5.

Dosing regimens evaluated for spectinamide 1599 in the dose-fractionation study (in terms of total daily dose)

Dosing frequency

2

10

40

100

Daily dose (mg/kg)
66
166

200

332

400

Study 2A
5x per week
(m-f) twice
5x per week
(m-f)
3x per week
(m,w,f)
2x per week
(m,r)
1x per week
(m)

1 BID

5 BID

20 BID

50 BID

100 BID

2 QD

10 QD

40 QD

100 QD

200 QD

10 TIW

40 TIW

100 TIW

10 BIW

40 BIW

10 QW

40 QW

200 BID

Study 2B
5x per week
(m-f) twice
3x per week
(m,w,f)
2x per week
(m,r)
1x per week
(m)

100 BID
66 TIW

166 BID

166 TIW

100 BIW
166 QW
Study 2C

5x per week
(m-f) twice
5x per week
(m-f)
3x per week
(m,w,f)
2x per week
(m,r)

50 BID
100 QD
166 TIW
100 BIW

BID- Twice daily for 5 consecutive days; m-f: Monday to Friday; QD- Once daily for 5 consecutive days; m-f: Monday to Friday; TIW - Thrice
weekly on Monday, Wednesday and Friday; BIW - Twice weekly on Monday and Thursday; QW- Once weekly on Monday
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Chromatographic Conditions
Chromatographic separations were carried out using a Shimadzu Nexera XR (LC20ADXR) liquid chromatography (Shimadzu Corporation, Kyoto, Japan) consisting of
two pumps, an online degasser, system controller, and an autosampler, using a Waters
Symmetry® 3.5 μm C8, 50 × 2.1 mm column (Waters, Milford, MA). The mobile phase
was solvent A (water with 1.6% nonafluoropentanoic acid and 0.7% formic acid) and
solvent B (90% acetonitrile with 0.8% nonafluoropentanoic acid and 0.35% formic acid)
in a gradient mode as follows: 0–0.5 min, 20% B; 0.5–1.6 min, 20–90% B; 1.6–2 min,
90% B; 2-2.5 min, 90-20% B, 2.5–3 min, 20% B at a flow rate of 0.5 mL/min. Analytes
were detected with a Sciex 5500 triple-quadruple mass spectrometer (Applied
Biosystems, Foster City, CA) with electrospray ionization in multiple reaction monitoring
mode Mass Spectrometric Conditions. The optimized multiple reactions monitoring
(MRM) conditions for spectinamide 1810 and 1599 and IS are given in Table 3-6. Data
were acquired and processed with Analyst software version 1.6.3 (Applied Biosystems,
Foster City, CA).

Stock Solutions, Calibrants, and Quality Controls
Stock solution (1 mg/mL) of spectinamides was prepared in water. A working
solution (1000 ng/mL) was prepared in mouse plasma and diluted serially to generate a
series of calibrants (0.98, 1.95, 3.91, 7.81, 15.63, 31.25, 62.5, 125, 250, 500, 1000
ng/mL). A fresh solution of spectinamides (independent of calibrants) was used to
prepare quality controls. Appropriate volumes of working solutions were added to mouse
plasma to yield the final concentrations of 33.33, 100, 300, 900 ng/mL. Each analytical
run consisted of one set (triplicate) of quality control samples scattered in between
calibrants and in vivo study samples. Linearity for calibrants in duplicate was assessed by
subjecting the spiked concentrations and the respective peak areas to least-square linear
regression analysis with and without intercepts, and a weighted least-square regression
(1/x or 1/x2). A suitable calibration model was chosen after examination of residuals and
coefficient of correlation in each case. The lower limit of quantitation (LLOQ) in the
standard curve measured with acceptable accuracy and precision from normal mouse
plasma was established as 0.98 ng/mL.

Concentration-Time Profile
Concentration-time data along with summary statistics for spectinamide 1810 and
spectinamide 1599 after administration of various doses in healthy animals are listed in
Tables 3-7 to 3-12. The peak (0.25h) and trough (8h) concentrations measured in plasma
samples from infected animals for spectinamide 1810 are plotted in Figures 3-2 and 3-3,
respectively. Similarly, peak and trough concentrations for spectinamide 1599 are plotted
in Figures 3-4 and 3-5, respectively.
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Table 3-6.

Optimized MRM conditions for spectinamide 1810 and 1599

Analytes Precursor ion Product ion Declustering Collision energy (eV)
potential (V)
45
25
1810
418.3 [M+H]+
207.1
487.2 [M+H]+

207.1

45

25

IS (1329) 453.0 [M+H]+

247.1

45

25

1599

Table 3-7.
Plasma concentration-time data after single dose SC administration of
spectinamide 1599 (50 mg/kg) to Balb/c mice
Time (h)
0.08
0.25
0.5
1
2
3
8
24

Spectinamide 1599
concentration (µg/mL),
n = 3 mice/time pt
81.3
42.9
55.0
66.9
89.5
116
51.1
53.9
29.0
2.41
2.59
3.39
0.538
0.483
0.261
0.1994
0.160
0.088
0.0449 0.1396 0.0592
0.00907 0.0168 0.01668

Median

Mean

STDEV

Range

GEOMEAN

GEOSD

55.0
89.5
51.1
2.59
0.483
0.160
0.0592
0.0167

59.7
90.8
44.6
2.80
0.428
0.149
0.0813
0.0142

19.7
24.5
13.7
0.520
0.147
0.0566
0.0510
0.00442

38.4
48.9
24.9
0.975
0.277
0.112
0.0947
0.00769

57.6
88.5
43.0
2.77
0.408
0.141
0.0719
0.01364

1.38
1.32
1.41
1.20
1.48
1.53
1.81
1.42
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Table 3-8.
Plasma concentration-time data after multiple dose SC administration
of spectinamide 1599 (QD5, TIW, and BIW, 200 mg/kg), to Balb/c mice
Time (h)

Spectinamide 1599
concentration (µg/mL),
n = 3 mice/time pt

Predose
0.08
0.25
1
3
8

0.130
255
270
82.4
0.730
0.330

0.130
393
368
57.2
1.26
0.410

0.160
286
344
62.4
1.76
0.320

0.140
311
327
67.3
1.25
0.353

Predose
0.08
0.25
1
3
8

0.0300
213
242
88.9
1.59
0.240

0.0400
228
266
54.2
1.16
0.330

0.0400
271
258
109
1.21
0.230

0.0367
237
255
84.0
1.32
0.267

Predose
0.08
0.25
1
3
8

0.270
299
358
128
1.47
0.170

0.0400
203
265
72.2
0.710
0.230

0.0200
203
497
101
0.730
0.250

0.110
235
373
100
0.970
0.217

Median

Mean
QD5
0.0173
72.4
51.1
13.3
0.515
0.0493
TIW
0.00577
30.1
12.2
27.7
0.235
0.0551
BIW
0.139
55.4
117
27.9
0.433
0.0416

STDEV

Range

GEOMEAN

GEOSD

0.130
286
344
62.4
1.26
0.330

0.0300
138
98.0
25.2
1.03
0.0900

0.139
306
325
66.5
1.17
0.351

1.13
1.25
1.18
1.21
1.56
1.14

0.0400
228
258
88.9
1.21
0.240

0.0100
58.0
24.0
54.8
0.430
0.100

0.0363
236
255
80.7
1.31
0.263

1.18
1.13
1.05
1.43
1.19
1.22

0.0400
203
358
101
0.730
0.230

0.250
96.0
232
55.8
0.760
0.0800

0.0600
231
361
97.7
0.913
0.214

3.85
1.25
1.37
1.33
1.51
1.22

Table 3-9.
Plasma concentration-time data after single dose SC administration of
spectinamide 1810 (50 mg/kg) to Balb/c mice
Time (h)
0.08
0.25
0.5
1
2
3
8
24

Spectinamide 1810
concentration (µg/mL),
n = 3 mice/time pt
147
106
157
139
127
141
63.7
59.6
51.1
9.08
14.0
6.19
0.380
0.410
0.480
0.0800 0.0800 0.120
0.0300 0.0500 0.0300
0.0100 0.0100 0.0100

Median

Mean

STDEV

Range

GEOMEAN

GEOSD

137
136
58.1
9.76
0.423
0.0933
0.0367
0.0100

27.0
7.57
6.43
3.95
0.0513
0.0231
0.0115
0.00

147
139
59.6
9.08
0.410
0.0800
0.0300
0.0100

51.0
14.0
12.6
7.81
0.100
0.0400
0.0200
0.00

135
136
57.9
9.23
0.421
0.0916
0.0356
0.0100

1.23
1.06
1.12
1.50
1.13
1.26
1.34
1.00
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Table 3-10. Plasma concentration-time data after multiple dose SC administration
of spectinamide 1810 (QD5, 50 mg/kg) to Balb/c mice
Time (h)
Predose
0.25
0.5
1
3
8

Spectinamide 1810
concentration (µg/mL),
n = 3 mice/time pt
0.0200 0.0400 0.0200
143
173
134
112
109
141
7.12
7.90
11.9
0.170
0.250
0.160
0.0300 0.160 0.0700

Median

Mean

STDEV

Range

GEOMEAN

GEOSD

0.0267
150
121
8.97
0.193
0.0867

0.0115
20.4
17.7
2.56
0.0493
0.0666

0.0200
143
112
7.90
0.170
0.0700

0.0200
39.0
32.0
4.78
0.0900
0.130

0.0252
149
120
8.75
0.189
0.0695

1.49
1.14
1.15
1.31
1.27
2.31

Table 3-11. Plasma concentration-time data after single dose SC administration of
spectinamide 1810 (200 mg/kg) to Balb/c mice
Time (h)
0.08
0.25
0.5
1
2
3
8
24

Spectinamide 1810
concentration (µg/mL),
n = 3 mice/time pt
579
525
545
432
553
576
235
243
301
24.5
23.7
31.9
0.920
1.23
1.48
0.390
0.320
0.330
0.110 0.0900 0.130
0.0500 0.0500 0.0400

Median

Mean

STDEV

Range

GEOMEAN

GEOSD

550
520
260
26.7
1.21
0.347
0.110
0.0467

27.3
77.4
36.0
4.52
0.281
0.0379
0.0200
0.00577

545
553
243
24.5
1.23
0.330
0.110
0.0500

54.0
144
66.0
8.20
0.560
0.0700
0.0400
0.0100

549
516
258
26.5
1.19
0.345
0.109
0.0464

1.05
1.17
1.14
1.18
1.27
1.11
1.20
1.14

Table 3-12. Plasma concentration-time data after multiple dose SC administration
of spectinamide 1810 (QD5, 200 mg/kg) to Balb/c mice
Time (h)
Predose
0.25
0.5
1
3
8

Spectinamide 1810
concentration (µg/mL),
n = 3 mice/time pt
0.0700 0.0800 0.0800
464
707
614
503
507
490
54.9
29.7
27.8
0.350
0.740
0.370
0.220
0.180
0.240

Median

Mean

STDEV

Range

GEOMEAN

GEOSD

0.0767
595
500
37.5
0.487
0.213

0.00577
123
8.89
15.1
0.220
0.0306

0.0800
614
503
29.7
0.370
0.220

0.0100
243
17.0
27.1
0.390
0.0600

0.0765
586
500
35.7
0.458
0.212

1.08
1.24
1.02
1.46
1.52
1.16
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Figure 3-2. Spectinamide 1810 peak plasma concentrations ln(ng/ml) in Infected mice for the different dosing regimens with
the same weekly dose (top line)
Doses are provided as mg/kg. The open circles represent observed trough plasma concentration values and the blue lines represent a
90 % confidence interval around the observed values. The grey shaded area is the 90 % confidence interval for population PK modelbased simulated values
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Figure 3-3. Spectinamide 1810 trough plasma concentrations ln(ng/ml) in infected mice for the different dosing regimens
with the same weekly dose (top line)
Doses are provided as mg/kg. The open circles represent observed trough plasma concentration values and the blue lines represent a
90 % confidence interval around the observed values. The grey shaded area is the 90 % confidence interval for population PK modelbased simulated values
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Figure 3-4. Spectinamide 1599 peak plasma concentrations ln(ng/ml) in infected mice for the different dosing regimens with
the same weekly dose (top line)
Doses are provided as mg/kg. The open circles represent observed trough plasma concentration values and the blue lines represent a
90 % confidence interval around the observed values. The grey shaded area is the 90 % confidence interval for population PK modelbased simulated values
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Figure 3-5. Spectinamide 1599 trough plasma concentrations ln(ng/ml) in infected mice for the different dosing regimens
with the same weekly dose (top line)
Doses are provided as mg/kg. The open circles represent observed trough plasma concentration values and the blue lines represent a
90 % confidence interval around the observed values. The grey shaded area is the 90 % confidence interval for population PK modelbased simulated values
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Microbiological Analysis

Enumeration of Bacterial Count in Lung Samples
After 4 weeks of treatment followed by 2 days of washout period, lungs were
harvested and homogenized for dilution and plated on Middlebrook 7H11 agar plates
supplemented with oleic acid-albumin-dextrose-catalase (OADC). Plates were incubated
at 37°C and CFU were enumerated after at least 21 days of incubation. In each study, to
enumerate the bacterial uptake from the low dose aerosol infection, 6 mice were
sacrificed on day 1 post-infection. On day 34 post-infection, 5 mice were sacrificed to
determine the bacterial load at the start of therapy. On day 62 post-infection, 5 Balb/c
untreated mice and 7 Balb/c mice dosed with vehicle were sacrificed to determine the
bacterial load in the untreated group and placebo group respectively. This information
was used for describing the natural bacterial growth. The viable CFU counts were
logarithmically converted for further data analysis.

Pharmacodynamic Analysis
After four weeks of therapy in mice chronically infected with Mtb
spectinamide1810 exhibited a dose-dependent decrease in the bacterial counts. The plot
of weekly dose as shown in Figure 3-6 with various combinations of dose and dosing
frequency vs. log CFU indicates a dose-dependent increase in reduction of bacterial
counts with higher weekly doses, but also suggests that higher doses with lower dosing
frequency result in better efficacy. For example, a weekly dose of 500 mg/kg when given
as 166 mg/kg TIW resulted in better efficacy compared to 100 mg/kg QD, which in turn
was better than 50 mg/kg BID. Similar trends with some exceptions were also observed
with dose fractionation of other weekly doses where intermittent dosing provided
improved efficacy relative to more frequent dosing. The dose-response plot for
spectinamide 1599 is depicted in Figure 3-7 and it displays a poor relationship between
dose and response.

32

Figure 3-6. Bacterial burden (log CFU) in the lungs of Mtb infected mice for the different dosing regimens of spectinamide
1810 with the same weekly dose (top line)
Doses are provided as mg/kg. The open circles represent observed log CFU values and the blue lines represent a 90 % confidence
interval around the observed values. The grey shaded area is the 90 % confidence interval for the PK/PD model-based simulated
values
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Figure 3-7. Bacterial burden (log CFU) in the lungs of Mtb infected mice for the different dosing regimens of spectinamide
1599 with the same weekly dose (top line)
Doses are provided as mg/kg. The open circles represent observed log CFU values and the blue lines represent a 90 % confidence
interval around the observed values. The grey shaded area is the 90 % confidence interval for the PK/PD model-based simulated
values
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CHAPTER 4.

POPULATION PHARMACOKINETIC ANALYSIS

Introduction
The PK assessments available in this analysis were conducted on data obtained
from both healthy and infected animals. Although due to practical restrictions limited
samples were collected from infected animals, intensive sample collection from healthy
animals would be adequate to understand the PK behavior of spectinamides in Balb/c
mice. To facilitate a reliable characterization of the pharmacokinetic parameters in all
study conditions and dosing regimens, we employed a population PK analysis approach
using nonlinear mixed-effects modeling. To stabilize the analysis despite the
experimental limitations, we integrated Bayesian priors into the modeling approach to
balance the current data set.

Population Pharmacokinetic Analysis in Healthy Animals
In the first step, a separate population PK model was developed for each
spectinamide to describe the pharmacokinetics of healthy animals. In the case of
spectinamide 1810, a total of 84 observations from 84 healthy animals, and for
spectinamide 1599 a total of 78 observations from 78 healthy animals as assessed in the
single and multiple-dose PK studies, were included. The concentration data were natural
log-transformed and modeled using a log-transform-both-sides (LTBS) approach [93].
The evaluation of the structural PK model was undertaken based on graphical exploratory
data analysis, basic goodness-of-fit plots, and previous PK knowledge of compounds
from the spectinamide series [11, 94].
For all models evaluated in this analysis, between-subject variability as shown in
Equation 4-1 was modeled as a log-normal distribution,
𝑃𝑖 = 𝑃𝑝𝑜𝑝 ∙ 𝑒 𝜂𝑖

Eq. 4-1

Where Pi is the parameter estimate for mouse i, Ppop represents the typical
population value for the parameter, and ηi is the independent random variable in mouse i,
described by a normal distribution with mean zero and variance ω2 , which corresponds to
a log-normal distribution for the parameter.
The residual unexplained variability (RUV) was characterized as an additive error
(Equation 4-2), which relates to a proportional error when using an LTBS approach,
such that:
𝑙𝑛(𝐶𝑖𝑗 ) = 𝑙𝑛( Ĉ𝑖𝑗 ) + 𝜀𝑖𝑗

Eq. 4-2
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Wherein(Cij ) is the natural logarithm of the jth observed concentration in the
mouse i, ln(Ĉij ) is the natural logarithm of the model predicted concentration for the jth
observation in the mouse i, and εij is the residual error characterized by a normal
distribution with mean zero and variance σ2 .
Bayesian Approach for Population Pharmacokinetic Analysis in Infected Animals
The Bayesian approach has been successfully implemented previously for the
estimation of PK parameters for poorly informative data, by incorporating prior
information obtained from more informative studies [95, 96]. In the present analysis,
parameter estimates obtained from healthy animals along with their distributions served
as Bayesian priors in the subsequent PK analysis in infected animals. The observations
from infected animals, i.e. 282 concentration-time data of spectinamide 1810 from 146
infected animals, and 241 concentration-time data from 141 infected animals for
spectinamide 1599, were modeled using the Bayesian priors and the healthy animal data
to improve robustness and stability of the parameter estimates. The structural model
along with interindividual and residual variability components was kept unchanged from
population PK analysis in healthy animals. The NONMEM model codes are provided in
Appendix A.

Results
Based on the biphasic distribution after SC administration, a two-compartment
model with first-order absorption was selected to describe the PK of spectinamide 1810
and 1599. The model for each spectinamide was parameterized in terms of first-order
absorption rate constant (Ka ), clearance (CL/F), central volume of distribution (Vc /F),
inter-compartmental clearance (Q/F), and peripheral volume of distribution (Vp /F) and
the analysis was performed for healthy and infected animals separately as well as jointly.
The corresponding parameter estimates along with their precision and between-animal
variability for healthy and infected animals are provided for spectinamide 1810 and 1599
in Tables 4-1 and 4-2, respectively. Spectinamides undergo rapid absorption from the
subcutaneous administration site with a short absorption half-life of <10 min. The drugs
displayed a biphasic PK profile with its volume of distribution mainly limited to the
extracellular fluid volume, with some peripheral distribution. Similar to other cationic
amphiphilic drugs, spectinamides may also have a high binding affinity towards
intracellular phospholipids, and slow-release from these sites are a plausible cause for the
prolonged terminal elimination half-life at low concentrations [97].
The analyses as well as a concurrently performed covariate modeling approach
for disease status and comparison of post-hoc estimates for healthy and infected animals
indicated that there is no relevant difference in PK parameters for both spectinamide
1810 and 1599 between healthy and infected animals. Based on our previous knowledge
of spectinamide PK behavior it is known that spectinamides are predominantly
eliminated by the renal route. To the best of our knowledge, no literature evidence
supports the alteration of renal function in Balb/c mice infected with Mtb. These findings
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Table 4-1.

Parameter estimates of final spectinamide 1810 PK model

Parameters
Ka (h-1)
Vc /F (L/kg)
Vp /F (L/kg)

Typical value
(%RSE)
Healthy
Infected
14 (12)
15.4 (8)
0.205 (5)
0.217 (3)
0.145
0.16 (12)
(16)

CL/F
(L/h/kg)

0.701 (2)

0.697 (2)

Q/F (L/h/kg)

0.0105
(16)

0.0089
(6)

RUV

Random variability*
(%RSE) [%Shrinkage]
Healthy
Infected

14.56 (30)
[17]

13.15 (24)
[59]

12.33 (35)
[44]

60 (8) [4]

Abbreviations: Ka , absorption rate constant; Vc /F, the volume of the central compartment
corrected for bioavailability; Vp /F, the volume of peripheral compartment corrected for
bioavailability; CL/F, clearance corrected for bioavailability; Q/F, intercompartmental
clearance corrected for bioavailability; *Random variability expressed as a % coefficient
of variation of between-animal variability or residual unexplained variability (RUV),
respectively.

Table 4-2.

Parameter estimates of final spectinamide 1599 PK model

Parameters
Ka (h-1)
Vc /F (L/kg)
Vp /F (L/kg)
CL/F
(L/h/kg)
Q/F (L/h/kg)

Typical value
(%RSE)
Healthy
Infected
9.46 (16)
6.64 (11)
0.382 (9)
0.241 (8)
1.75 (58)
1.15 (23)
0.941 (6)

0.753 (2)

0.0397
(24)

0.0391
(6)

RUV

Random variability*
(%RSE) [%Shrinkage]
Healthy
Infected

30.3 (16)
[18]

29 (9) [28]

21.65 (26)
[42]

49.19 (11)
[17]

Abbreviations: Ka , absorption rate constant; Vc /F, the volume of the central compartment
corrected for bioavailability; Vp /F, the volume of peripheral compartment corrected for
bioavailability; CL/F, clearance corrected for bioavailability; Q/F, intercompartmental
clearance corrected for bioavailability; *Random variability expressed as a % coefficient
of variation of between-animal variability or residual unexplained variability (RUV),
respectively
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support our hypothesis in aim 1 and we demonstrate by population PK analysis that the
disease status does not have an impact on the PK behavior of spectinamides.
The basic goodness-of-fit plots for the final PK models are provided in Figures
4-1 and 4-2 for spectinamide 1810 and 1599 respectively. The visual predictive checks
(VPCs) for model diagnostics are plotted by overlaying median and 90 % prediction
interval of model predicted values and observed values. The VPCs for spectinamide 1810
are shown in Figure 4-3 for healthy animal PK and in Figures 4-4 and 4-5 for infected
animal PK. Likewise, for spectinamide 1599 VPCs for healthy animal PK are shown in
Figure 4-6 and for infected animal PK VPCs are given in Figures 4-7 and 4-8.
Additionally, in the case of infected animal PK, VPCs for peak and trough concentration
is created as shown in Figures 3-2 and 3-3 for spectinamide 1810 and Figures 3-4 and
3-5 for spectinamide 1599.

Figure 4-1.

Goodness of fit plot for the final PK model of spectinamide 1810
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Figure 4-2.

Goodness of fit plot for the final PK model of spectinamide 1599

Figure 4-3. Spectinamide 1810 plasma concentrations-time profiles (ng/ml) in
healthy mice
Doses are provided as mg/kg. The closed circles represent observed plasma concentration values,
the red line represents the median of simulated values and the shaded area is the 90 % confidence
interval for population PK model-based simulated values. SD-single dose; MD, Multiple-dose
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Figure 4-4. Spectinamide 1810 plasma concentrations ln (ng/ml) in infected mice (BID & QD)
Doses are provided as mg/kg. The closed circles represent observed plasma concentration values, the red line represents the median of
simulated values and the shaded area is the 90 % confidence interval for population PK model-based simulated values. BID, twice
daily; QD, Once daily
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Figure 4-5. Spectinamide 1810 plasma concentrations ln (ng/ml) in infected mice (TIW, BIW & QW)
Doses are provided as mg/kg. The closed circles represent observed plasma concentration values, the red line represents the median of
simulated values and the shaded area is the 90 % confidence interval for population PK model-based simulated values. TIW, Thrice
weekly; BIW, Twice weekly; QW, once weekly
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Figure 4-6.

Spectinamide 1599 plasma concentrations ln (ng/ml) in healthy mice

Doses are provided as mg/kgThe closed circles represent observed plasma concentration
values, the red line represents the median of simulated values and the shaded area is the
90 % confidence interval for population PK model-based simulated values. SD-single
dose; QD, Once daily; TIW, Thrice weekly; BIW, Twice weekly
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Figure 4-7. Spectinamide 1599 plasma concentrations ln (ng/ml) in infected mice (BID & QD)
Doses are provided as mg/kg. The closed circles represent observed plasma concentration values, the red line represents the median of
simulated values and the shaded area is the 90 % confidence interval for population PK model-based simulated values. BID, twice
daily; QD, Once daily
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Figure 4-8. Spectinamide 1599 plasma concentrations ln (ng/ml) in infected mice (TIW, BIW & QW)
Doses are provided as mg/kg. The closed circles represent observed plasma concentration values, the red line represents the median of
simulated values and the shaded area is the 90 % confidence interval for population PK model-based simulated values. TIW, Thrice
weekly; BIW, Twice weekly; QW, once weekly
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CHAPTER 5.

IDENTIFICATION OF EXPOSURE DRIVERS FOR EFFICACY

Introduction
To better predict the efficacy/potency of the antibacterial agent, PK/PD indices
are a very helpful tool for making an informed decision about the candidate during the
preclinical stage. This method is useful for assessing the relationship between the
summary endpoints of the in vivo drug exposure parameters relative to MIC as an in vitro
potency parameter and the efficacy. Efficacy is measured in terms of treatment-induced
reduction in the total bacterial load with respect to control. The commonly used in vivo
drug exposure parameters relative to MIC which are nothing but the PK/PD indices are;
the ratio of maximum drug concentration to the MIC (Cmax/MIC), area under the drug
concentration-time curve to the MIC (AUC/MIC) and, the extent of time drug
concentration remains above MIC (% T above MIC). The parameter which shows a better
correlation with the efficacy is considered the main driver for the efficacy. The
identification of drivers for the efficacy is critical in deciding optimal dose and dosing
frequency for anti-bacterial agents.

Methodology
Based on the individual PK parameters obtained by post-hoc estimation from the
population PK model and the known low plasma protein binding of spectinamide 1810
(39%) and spectinamide 1599 (30%) the PK/PD indices Cmax/MIC, AUC/MIC, and %T
above MIC for unbound concentrations were calculated at steady state, using the
previously determined MIC value of 1.6 mg/L for spectinamide 1810 and 0.8 mg/L for
spectinamide 1599 [13]. Cmax was the model-predicted maximum concentration achieved
after administration of the last dose, AUC, and time for which drug concentration was
above MIC were calculated for the period equals to the longest dosing interval i.e. one
week (168 h). Log CFU vs. PK/PD indices were plotted, and the corresponding
coefficient of determination was calculated.

Results
To further address the question of whether increased dose fractionation has a
greater potential in achieving optimal spectinamide therapy or not, the relationship of
bacterial kill relative to PK/PD indices that are frequently used in anti-bacterial therapy
were investigated. Figures 5-1 and 5-2 demonstrate the relationship between PK/PD
indices and log CFU for spectinamide 1810 and spectinamide 1599, respectively based
on the results of the dose fractionation study. In the case of spectinamide 1810,
AUC/MIC and Cmax/MIC show a strong correlation with log CFU reduction, whereas %T
above MIC exhibited only a weak relationship in the reduction of CFU.
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Figure 5-1. The relationship between PK/PD indices and log CFU for
spectinamide 1810
A: Log CFU vs Cmax/MIC; B: Log CFU vs AUC/MIC; C: Log CFU vs %Time above
MIC
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Figure 5-2. The relationship between PK/PD indices and log CFU for
spectinamide 1599
A: Log CFU vs Cmax/MIC; B: Log CFU vs AUC/MIC; C: Log CFU vs %Time above
MIC
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These results are in line with the previous finding of our lab from previously
conducted in vitro experiments and support our hypothesis for aim 2 that suggests the
anti-bacterial effect of spectinamide against mycobacteria is largely driven by exposure
and peak concentrations, rather than exceeding a minimum drug level.
However, in the case of spectinamide 1599, the findings of in vivo studies are not
in accordance with the previous in vitro results. We did not observe a significant
correlation between PK/PD indices and log CFU reduction and, hence we could not
clearly identify the major drivers for the efficacy for the backup spectinamide. This is
unlikely for an antibacterial agent to not find drivers for the efficacy. The potential
explanation for this discrepancy could be the failure to translate in vitro potency of
spectinamide 1599 into in vivo efficacy or limitations in the experimental procedure,
failed to produce anticipated efficacy.
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CHAPTER 6. MECHANISM-BASED PK/PD MODELING WITH
CONSIDERATION OF PAE TO CHARACTERIZE DOSE-EXPOSURERESPONSE RELATIONSHIP

Introduction
Dose-exposure-response analysis has become an integral part of the drug
development process. For antibacterial agents, it describes the magnitude of reduction in
bacterial count as a function of doses/exposure and provides valuable information about
the dose range and administration that are very crucial for clinical practice. Numerous
PK/PD model-based approaches have been employed to characterize the dose-exposureresponse relationship and the output of these exercises could lead to quantitative-based
decision making.
In this section, we explored mechanism-based PK/PD modeling and simulation
tools to characterize the dose-exposure-response relationship of lead and backup
spectinamide for their efficacy in dose-ranging and dose fractionation studies conducted
on Mtb infected Balb/c mice. Additionally, since spectinamides are known to exhibit
PAE, the effect of inclusion of PAE strategies to this modeling framework was
considered for the scope of this investigation.

Bacterial Growth Kinetic Model
Before developing an integrated PK/PD model for antibacterial agents, it was
important to have a mathematical model to describe the natural growth kinetics of
bacteria in absence of drug treatment. Due to practical limitations, only one observation
was collected per animal and all the samples were collected at the same time after four
weeks of treatment in our data set. Thus, there was a deficit of a sufficient number of
time points to determine the bacterial kill kinetics. Therefore, a simple one population
bacterial growth kinetic model, as expressed in Equation 6-1 was used to describe
natural growth kinetics of Mtb in chronically infected mice. A logistic growth function
was applied to capture the growth kinetics, and host-mediated killing was induced by a
first-order kill rate constant Kir.
𝑑𝑁
𝑑𝑡

= 𝐾𝑔𝑠 ∙ (1 −

𝑁
Nmax

) ∙ 𝑁 − 𝐾𝑖𝑟 ∙ 𝑁

Eq. 6-1

Here, Kgs and Kir represent growth and host-mediated kill rate of bacteria,
respectively. N is the number of bacteria at any given time, which eventually approaches
a maximum Nmax. The parameters describing natural growth kinetics of Mtb were
estimated based on the time course of log CFU obtained from current and previous
studies performed at Colorado State University using the same mouse and bacterial
strains.
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PK/PD Modeling with PAE Estimation
Once the natural bacterial growth model had been established, the next step was
to integrate the drug effect into it. Based on the individual post-hoc estimates from the
population PK analysis, a sequential PK/PD analysis was performed by linking exposure
to efficacy. Different modeling approaches were explored. These include direct as well as
indirect link approaches using sigmoidal Emax functions that link drug concentrations to
bacterial kill rates [76, 100].
In vitro experiments have previously shown that spectinamides exhibit a long
PAE ranging between 19 and 137 h [11, 13]. As per the preliminary results, spectinamide
1810 and spectinamide 1599 exhibit PAE of 20 h and 133 h, respectively [13]. Based on
this, we explored the potential of an in vivo PAE by integrating and testing different PAE
components with the bacterial kill component of the PK/PD model. This was modeled by
creating a hypothetical effect-compartment concentration that was identical to the central
compartment in the model until the peak concentration in each dosing interval, but then
either persisted at peak concentration for a defined time period, declined after the peak
concentration but with a slower decline than in plasma, or a combination thereof. The
major difference to a classic effect compartment approach [101] lies in the lack of delay
in concentration and effect compartment concentration before peak concentrations. This
dynamic behavior was inspired by one of the current theories that PAE is driven by
prolonged persistence of a drug at the binding site or within the subcellular target space
in the bacteria [31, 87].

Methodology
The CFU data were log-transformed by taking the decadic logarithm to CFU.
Similar to the PK analysis, an LTBS approach was also used for the PK/PD model, and
RUV was characterized using an additive error. As a single sample was available per
animal, it was not feasible to separately estimate between-animal variability; hence only
the RUV characterized as the additive error was estimated in the model. Study-specific
fixed effect parameters and random effects like RUV were estimated to assess the studyspecific differences. The basic goodness-of-fit plots, objective function value (OFV), the
Akaike information criterion (AIC) (Equation 6-2) were considered while comparing
structural models. The AIC was considered to compensate better fit due to model
complexity using the following equation [39]
𝐴𝐼𝐶 = 𝑂𝐹𝑉 + 2 ∙ 𝑁𝑃𝑅

Eq. 6-2

NPR is the total number of parameters estimated in each model including all fixed
and random effects parameters.
The systematic steps followed to develop the final integrated PK/PD model along
with the NONMEM codes and goodness of fit plots for several models tested during the
model building process are provided in Appendix B. The final model selected that most
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adequately described the exposure-response relationship for the spectinamide compounds
was an integrated PK/PD model with PAE effect, where the killing effect of spectinamide
compounds is linked to plasma concentrations via a PAE model component in which the
drug decline after peak plasma concentrations is delayed following a first-order process,
characterized by a rate constant KPAE as shown in Figure 6-1. The parameters related to
the bacterial natural growth model were fixed during the PK/PD analysis to the
previously established values and only the drug effect parameters were estimated. With
the addition of a drug effect to the natural growth model, Equation 6-1 was then
modified to Equation 6-3.
𝑑𝑁
𝑑𝑡

= 𝐾𝑔𝑠 ∙ (1 −

𝑁
𝑁𝑚𝑎𝑥

) ∙ 𝑁 − 𝐾𝑖𝑟 ∙ 𝑁 −

𝐾𝑘𝑖𝑙𝑙𝑚𝑎𝑥 ∙ (𝐶𝑃𝐴𝐸 )𝛾
(𝐸𝐶50 )𝛾 +(𝐶𝑃𝐴𝐸 )𝛾

∙𝑁

Eq. 6-3

Where CPAE represents the concentration in the hypothetical PAE compartment at
time t, Kkillmax is the maximum kill rate induced by spectinamide compound, EC50 is the
concentration of spectinamide compound at half-maximal kill rate, and γ is the Hill
coefficient.
In the initial stages of model development, models were evaluated based on OFV
and basic goodness-of-fit plots such as observed vs. predicted values, and distribution of
weighted and conditional weighted residuals across time and predicted values. In the later
stages, simulation-based methods including visual predictive check and bootstrap
analysis were used for model qualification. In the visual predictive check, the final model
was used to simulate 1,000 replicates of the original data, and median, 5th and 95th
percentile of the simulated concentrations and CFU values were compared with the
observed data. Likewise, a nonparametric bootstrap analysis was executed with 1,000
replicates to assess the robustness of the final parameter estimates.
Modeling and simulations were performed using the software packages
NONMEM (v.7.4; Icon Development Solutions, Ellicott City, MD, USA), PsN (v.4.9.0)
[102], and Pirana (v.2.9.8, Certara, Princeton, NJ, USA). Plots were generated using
GraphPad Prism (v.7, GraphPad Software, San Diego, CA, USA) or the ggplot2 package
in R (v.3.5.1, R Foundation for Statistical Computing, Vienna, Austria). AUC was
calculated using the metrumrg package in R (Metrum ResearchGroup, Tariffville, CT,
USA).

Results
The developed one-population bacterial growth model adequately described the
natural growth kinetics of Mtb in infected mice. The in vivo growth rate constant (Kgs)
for Mtb was estimated to be 0.0372 h-1 (Table 6-1) and the corresponding doubling time
was calculated as 18.6 h, which is within the range reported in the literature (13–80 h)
[66, 98, 99]. Additionally, a model-based VPC plot was also created as shown in Figure
6-2 and it suggests the natural growth kinetic model reasonably describes the observed
time course of bacterial count obtained from untreated infected animals.
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Figure 6-1. Mechanism-based PK/PD model to establish the relationship between
exposure and response
Abbreviations: Ka , absorption rate constant; Vc /F, the volume of the central compartment
corrected for bioavailability; Vp /F, the volume of peripheral compartment corrected for
bioavailability; CL/F, clearance corrected for bioavailability; Q/F, intercompartmental
clearance corrected for bioavailability. C, CP, and CPAE represent spectinamide
compound concentration in central, peripheral, and hypothetical PAE compartment
respectively; TAD, time after dose; Tmax represents time corresponds to maximum plasma
concentration (Cmax) of spectinamide; Kkillmax, maximum kill rate induced by
spectinamide; EC50, the concentration of spectinamide at half of Kkillmax; γ, hill function;
KPAE, the first-order rate constant for dissipation of post-antibiotic effect; Kgs, first-order
growth rate constant; N is the number of bacteria at any given time and which eventually
approaches a maximum Nmax; Kir, first-order death rate constant based on natural
bacterial death and host immune response
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Table 6-1.

Parameter estimates describing natural growth kinetics of Mtb
Parameters
Kgs (h-1)
Kir (h-1)
Log Nmax
Log CFUI
RUV

Typical value
(%RSE) [%Shrinkage]
0.0372 (4)
0.00146 (1)
6.11 (1)
1.77 (3)
43.7 (11) [3]

Abbreviations: Kgs, first-order growth rate constant; Nmax, the maximum number of
bacteria; Kir, first-order death rate constant induced by the immune reaction; Log CFUI,
inoculum size on day 1, RUV, % coefficient of variation of residual unexplained
variability.

Figure 6-2. Time course of Mtb in untreated Balb/c mice
The closed circle represent observed values, red line and shaded are represent median and
90 % confidence interval of bacterial growth kinetic model predicted values
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For the quantitative characterization of spectinamide 1810’s antibacterial activity,
the PAE concentration predicted based on the central compartment concentrations was
linked to drug effect as an additional kill rate of the bacteria via a sigmoidal Emax-type
model. Initially, the PK/PD analysis was conducted only on the data from Study 1.
Different PAE models were explored. Estimation of either a combination of extension of
the peak plasma concentration over time and a subsequent slow first-order elimination or
a slow first-order elimination from the effect compartment resulted in comparable fits
with similar OFV. However, both approaches provided a better fit (ΔOFV ~24) when
compared to using an extension of the peak plasma concentration alone. Based on the
principle of parsimony, we decided to select the model with a decline in the PAE effect
determined by a first-order elimination rate constant (KPAE) alone for further data
analysis. The data from study 2 was subsequently included in the analysis. To account for
study-specific differences, the study was tested as a covariate either on fixed effect
parameters EC50 and Kkillmax or on random effect parameters. Study-specific effects on
fixed effect parameters were determined using the relationship shown in Equation 6-4
𝑃 = Θ1 ∙ (Θ2 )𝑆𝑇𝑈𝐷𝑌

Eq. 6-4

Where P represents the typical value of the parameter in the population, STUDY
is an indicator variable equal to 0 for study 1 and 1 for study 2, Θ1 is the typical value of
P for study 1, and Θ2 is the multiplicative factor describing the increase or decrease in P
in study 2.
The incorporation of study-specific differences on Kkillmax and estimating
different random error distributions for each study provided the best fit and maximum
drop in objective function as compared to analyzing the data without accounting for study
differences. The resulting parameter point estimates, as well as bootstrap, derived median
and confidence intervals are presented in Table 6-2, and the corresponding basic
goodness-of-fit plots for the final model are shown in Figure 6-3. A VPC showing the
congruence between the actual log CFU data and the PK/PD model-predicted simulations
for the different dose levels and dosing regimens is integrated into Figure 3-6.
In a similar fashion mechanism-based, PK/PD model building and model
validation process was implemented for spectinamide 1599. The final model-derived
parameters are listed in Table 6-3. The corresponding basic goodness-of-fit plots and
VPC plot are shown in Figures 6-4 and 3-7, respectively.
In conclusion, mechanism-based PK/PD modeling and simulation tools were
successfully employed to characterize the dose-exposure-response relationship for the
spectinamides under investigation. Spectinamides follow a defined dose-exposureresponse relationship. The higher slope factor for lead spectinamide 1810 (1.57) suggests
a steeper relationship between exposure and response as compared to backup
spectinamide 1599 (0.172). Model estimated EC50 values for spectinamide 1810 and
1599 were 80.4 μg/mL and 287.0 μg/mL, respectively. This suggests the lead
spectinamide demonstrated superior potency compared to the backup spectinamide
against Mtb in vivo studies performed on Balb/c mice.
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Table 6-2.
Parameter estimates with a bootstrap result for final PK/PD model of
spectinamide 1810

Kkillmax (h-1)
EC50 (μg/mL)
γ

Parameter estimates
(%RSE)
0.0375 (5.1)
80.4 (60.6)
1.57 (21.3)

PAE (h-1)

0.0138 (78.3)

Parameters

Study specific Kkillmax
difference
RUV1
RUV2

Bootstrap result median
[90% CI]
0.0370 [0.0350 - 0.0410]
83.4 [42.4 - 143.4]
1.1650 [1.166 - 2.470]
0.0140 [0.00442 0.0244]

1.15 (4)

1.15 [1.075 - 1.226]

28.39 (12.1)
17.35 (27.3)

27.73 [24.56 - 30.81]
016.46 [12.33 - 21.0]

Abbreviations: Kkillmax, maximum kill rate induced by spectinamide 1810; EC50, the
concentration of spectinamide 1810 at half of Kkillmax; γ, hill function; PAE, postantibiotic effect as elimination rate constant; Study-specific Kkillmax, multiplicative factor
on Kkillmax; RUV1&2, % coefficient of variation of residual unexplained variability for
study 1 and study 2 respectively

Figure 6-3.

Goodness of fit plot for the final PK/PD model of spectinamide 1810
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Table 6-3.
Parameter estimates with a bootstrap result for final PK/PD model of
spectinamide 1599
Parameters
Kkillmax (h-1)
EC50 (μg/mL)
γ
PAE (h-1)
Study specific Kkillmax
difference
RUV1
RUV2

Parameter estimates
(%RSE)
0.0683 (18)
287 (189)
0.172 (21)
0.0196 (80)

Bootstrap result median
[90% CI]
0.0763 [0.50 - 0.0872]
380 [132.9 - 1465.2]
0.160 [0.111 - 0.253]
0.0201 [0.00302 - 0.0678]

0.88 (6)

0.875 [ 0.760 - 0.950]

28.74 (20)
28.74 (22)

27.67 [21.63 - 34.35]
27.67 [20.64 - 34.21]

Abbreviations: Kkillmax, maximum kill rate induced by spectinamide 1599; EC50, the
concentration of spectinamide 1599 at half of Kkillmax; γ, hill function; PAE, postantibiotic effect as elimination rate constant; Study-specific Kkillmax, multiplicative factor
on Kkillmax; RUV1&2, % coefficient of variation of residual unexplained variability for
study 1 and study 2 respectively

Figure 6-4.

Goodness of fit plot for the final PK/PD model of spectinamide 1599
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CHAPTER 7.

SUMMARY

Characterization of the exposure-response relationship is a crucial step in the dose
selection process for novel antibiotic agents. In this study, we have integrated the
exposure and anti-infective response data of an extensive dose fractionation study for
lead and backup spectinamide compounds to derive a model-based PK/PD assessment of
its response in a mouse model of Mtb infection. In this context, we successfully
implemented a novel modeling framework that supported PAE as part of the mechanism
of action for spectinamides under investigation. Additionally, we also used a PK/PD
index-based approach to guide the dose selection process, which indicated that
spectinamide 1810 exhibits concentration- and exposure-dependent killing in an in vivo
system. The findings from both analyses/approaches, clearly highlight a superior efficacy
with higher doses that were administered less frequently over smaller doses administered
more frequently while maintaining a constant weekly dose level.
The collection of series of blood samples for PK assessments from infected
animals is challenging and usually prohibitive due to potential effects on in vivo efficacy.
In the current analysis, we, therefore, combined a sparse sampling design in infected
animals with a population PK analysis approach that used concentration data from
densely sampled healthy animals and Bayesian principles to stabilize the pharmacokinetic
analysis for infected animals. While this is an approach that has so far only rarely been
used in preclinical development, it is more widely applied in clinical drug development
for populations where only limited sampling is available, for example, to bridge PK data
from adult to pediatric populations [103, 104]. We used the same methodology to bridge
between the PK studies of densely sampled healthy animals and sparsely sampled
infected animals. The approach steered the modeling process to derive reliable
parameters for healthy as well as infected animals. Spectinamides are mainly eliminated
by the renal route in the unchanged form [11] and to the best of our knowledge, there is
no published data that indicates kidney function is affected by Mtb infection in mice. This
supports our finding of no difference in the PK behavior of lead spectinamides in healthy
and infected animals.
The evaluation of PK/PD indices for spectinamide 1810 indicates that Cmax/MIC
and AUC/MIC are better predictors of in vivo efficacy than %T above MIC. This
suggests that spectinamide 1810 exhibits concentration- and exposure-dependent rather
than time-dependent bacterial killing in Mtb-infected mice. This observation is in line
with our previous in vitro observations for spectinamide 1599, a precursor molecule of
spectinamide 1810 [91]. Similar patterns were also observed for existing first-line antiTB agents. Monotherapy studies conducted on preclinical models showed that microbial
kill for INH, RIF, PZA, and EMB was linked with either Cmax/MIC, AUC/MIC, or both
[57, 82, 83, 105-107]. In contrast, pretomanid displayed a time-dependent killing pattern,
and %T/MIC correlated best with bactericidal activity in dose fractionation studies
performed in mice [84]. However, in the present study, surprisingly spectinamide 1599
did not show correlation for any of the PK/PD indices with the efficacy. Future studies
are warranted to re-evaluate PK/PD indices of spectinamide 1599.
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Several mechanism-based modeling approaches have been reported to describe
the natural growth of Mtb in vivo. These include more simplistic models in which
bacterial growth is pragmatically assumed to occur in a homogenous bacterial population
and is limited by a maximum bacterial number with capacity-limited or logistic growth
functions [76, 91]. More complex models with two subpopulations have also been
explored under the assumption that a growing population under unfavorable conditions
gets converted into a dormant, resting, or slow-growing population [67]. A multistate
model for TB consisting of fast, slow, and non-replicating bacterial states was applied for
a pharmacometric analysis of rifampicin [72]. Most of these models were used to
characterize PK/PD relationships for in vitro time-kill experiments or in few cases for in
vivo studies partially supported by parameters obtained from in vitro experiments. To
allow the characterization of the complex dynamics of these models, a series of multiple
bacterial counts are needed that provide a time course of CFU count development over a
prolonged period. In the present study, all bacterial count samples from different dose
groups were collected at the same time after the termination of therapy. Therefore, our
data did not contain sufficient information to support these more complex modeling
approaches, and a simpler one population model was used. This model was able to
adequately describe the growth kinetics of Mtb and the drug effect of lead spectinamides
in our analysis.
Many antibacterial agents are known to exhibit a PAE. Therefore, along with PK
and PD considerations, it is important to incorporate PAE knowledge in designing dosing
regimens for anti-infective agents, especially for compounds such as spectinamide 1810
and spectinamide 1599 that are known to cause PAE in in vitro system [13]. To the best
of our knowledge, PAE has so far not been previously implemented in PK/PD modeling
strategies. One of the potential mechanisms considered for PAE is a longer persistence of
drug in subcellular fractions of the affected bacteria relative to the surrounding tissue
environment or host plasma. Based on that notion, we designed a PK/PD model with a
hypothetical PAE compartment for the anti-bacterial activity to characterize the doseexposure-relationship. The inclusion of the PAE compartment significantly improved the
model fit of the data and rationalized the efficacy patterns observed in the different dose
groups of the dose fractionation studies.
While investigating potential study-specific differences in our two sub-studies for
each spectinamide, we found that there are study-specific differences in Kkillmax and that
resulted in slightly different efficacies at comparable doses. Differences in bacterial load
at the start of the treatment between sub-studies could have been the potential reason for
achieving different kill rates, however future studies to understand the effect of bacterial
load on efficacy are still warranted. A study design to evaluate the influence of the route
of administration and inoculum size on the efficacy of first-line anti-TB agents
demonstrated superior therapeutic outcomes measured in terms of reduction of bacterial
load in lungs and extrapulmonary sites in IT-infected mice with comparatively lower
inoculum size as compared to IV-infected mice [108].
In conclusion, pharmacometrics based PK/PD modeling and simulation tools were
successfully implemented to characterize the dose-exposure-response relationship and
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determine the antibacterial efficacy of the spectinamides 1810 and 1599. These
spectinamides under investigation exhibited a dose-exposure-response relationship, with
lead spectinamide 1810 demonstrating a steeper response as a function of change in
dose/exposure, whereas backup spectinamide 1599 demonstrated a shallow relationship
between dose/exposure and response. Being promising candidates, it is expected that in
the near future both spectinamide 1810 and spectinamide 1599 will undergo further
screening for efficacy in other pre-clinical models. The comprehensive analysis work on
the characterization of the exposure-response relationship of lead and backup
spectinamide in a murine TB model presented here provides the basis for further studies
by establishing a rationale model-based framework for in vivo antimycobacterial activity
based on the integration of pharmacokinetic/ pharmacodynamic knowledge.
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APPENDIX A. FINAL POPULATION PK MODEL

Final Population PK model
;; 1. Based on: run177
;; 2. Description: 1810 healthy and Infected_PK-Prior-high KA-1
;; x1. Author: Santosh Wagh
; RUN166
$PROBLEM 1810 healthy animal PK
$DATA Lee1810_PK-All.CSV IGNORE= C
$INPUT C ID TIME AMT ADDL II DV EVID MDV STAT
$PRIOR NWPRI NTHETA=5, NETA=1, NEPS=1
$SUBROUTINE ADVAN4 TRANS4
$PK
TVCL=THETA(1)
CL=TVCL*EXP(ETA(1))
TVV2 = THETA(2)
V2 = TVV2;*EXP(ETA(2))
V3 = THETA(3)
Q = THETA(4)
KA = THETA(5)
S2=V2/1000
$ERROR
FLAG = 0
IF (F.EQ.0) FLAG = 1
IPRED = LOG(F+FLAG)
IRES=DV-IPRED
IWRES=IRES/IPRED
Y= IPRED + EPS(1)
$THETAP
0.701 FIX
0.205 FIX
0.145 FIX
0.0105 FIX
14 FIX
$THETAPV BLOCK(5)
2.88E-04 FIX
-1.30E-05 1.26E-04
1.73E-05 1.15E-04 5.23E-04
1.77E-05 -1.22E-05 -4.34E-06 2.94E-06
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-8.12E-03 1.45E-02 1.14E-02 -1.71E-03 2.84E+00
$OMEGAP
0.0212 FIX
$OMEGAPD
21.88 FIX ; DF=2*[(omega estimates from previous analysis)/(SE of omega of previous
analysis)]**2 =2*[(0.0212)/0.00641)**2]=21.88
$SIGMAP
0.0152 FIX
$SIGMAPD
16.64 FIX; ; DF=2*[(Sigma estimates from previous analysis)/(SE of Sigma of previous
analysis)]**2 =2*[(0.0152)/0.00527)**2]=16.64 SE obtained from lst files
$THETA
(0,0.9,5);CL TH1
(0,0.2,5);V2 TH2
(0,0.1,1000);V3 TH3
(0,0.01,1000000);Q TH4
(1,10,30);KA TH5
$OMEGA
0.5
;0.5
$SIGMA
0.5
$ESTIMATION MAXEVAL=2000 PRINT=5 METHOD=1 INTERACTION POSTHOC
MSF=166.MSF
$COVARIANCE MATRIX=R PRINT=E UNCONDITIONAL
$TABLE ID TIME AMT DV IWRES IPRED CWRES NOPRINT ONEHEADER
FILE=sdtab178
$TABLE ID CL V2 Q V3 KA NOPRINT ONEHEADER FIRSTONLY FILE=patab178
;$TABLE ID NOPRINT ONEHEADER FILE=catab178
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APPENDIX B. MECHANISM-BASED PK/PD MODEL DEVELOPMENT

We have used a mechanism-based PK/PD model to characterize the doseexposure-response relationship of lead and backup spectinamide. In this section, we
elaborately describe the mechanism-based PK/PD model building process for
spectinamide 1810. It includes exploration of numerous PK/PD models reported for antiTB agents, consideration of the PAE component, and deliberation and rationale behind
the selection of one model over others, and lastly development of the final model.
Although several models including some quite complicated ones have been
reported to describe natural growth kinetics for Mtb, considering limited sampling design,
we have decided to move forward with one of the simplest one population growth kinetic
model, because all observations were collected at the same point and a single log CFU
measurement per animal was available.
The NONMEM code for the initial model is provided under Model 1. The
bacterial growth was captured by growth rate constant Kgs, maximum bacterial growth
was limited by a logistic growth function, and bacterial death induced by the mouse
immune system was defined by a death rate constant. The drug effect as an additional kill
function was introduced by the sigmoidal Emax function. The drug effect parameters
including Emax, EC50, and γ, were estimated. We have not estimated between animal
variability on any of the fixed effect parameters, as we have only one observation per
animal. Therefore, in the basic goodness of fit plots we see identical plots for both
individual and population predicted versus observed values. Therefore, we have plotted
the population predicted versus observed values only. The plot for population predicted
versus observed values for Model 1 is shown in Figure B-1.

Figure B-1.

Observed vs population prediction for Model 1
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Model 1
;; 1. Based on: XX
;; 2. Description: ADVAN 13 TOL6- one population 1810 treatment data
;; x1. Author: Santosh Wagh
$PROBLEM DYNAMIC TIMEKILL 1810
$INPUT C ID TIME AMT ADDL II EVID MDV FREQ CMT DV ICL IV2 IQ IV3 IKA
;AMT is in mg
$DATA merg1810-PKPD.csv IGNORE=C
$SUBROUTINE ADVAN13 TOL6
$MODEL
NCOMP=4
COMP = (DEPOT,DEFDOSE)
COMP = CENTRAL
COMP = PERPIPH
;total number of of cells
COMP = Bact
;bacteria
$PK
;PK MODEL
CL = ICL ; L/hr/KG
V2 = IV2 ; L/KG
Q = IQ
V3 = IV3
KA = IKA
KEL = CL/V2 ; hr-1
K23 = Q/V2
K32 = Q/V3
S2 = V2
;PD MODEL
KGS = (THETA(1)/100) ;bacterial growth rate constant
NMAX = (10**THETA(2))*EXP(ETA(1))
CFU4 = (10**THETA(3));*EXP(ETA(2))
KIR = THETA(4)/1000
IMAX = THETA(5)
IC50 = THETA(6)
HILL = THETA(7)
A_0(1) = 0.0000001
A_0(4) = CFU4
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$DES
DADT(1) = -KA*A(1)
DADT(2) = KA*A(1) + K32*A(3) - KEL*A(2) - K23*A(2)
DADT(3) = K23*A(2) - K32*A(3)
CP = (A(2)/S2) + 0.0001
DRUG = IMAX*(CP**HILL)/(IC50**HILL + CP**HILL)
DADT(4) = KGS*A(4)*(1-(A(4)/NMAX)) - KIR*A(4) - DRUG*A(4)
$ERROR
A4 = A(4)
FLAG = 0
IF (F.EQ.0) FLAG = 1
IPRED=LOG10(A4)
IRES=DV-IPRED
W=1
IWRES=IRES/W
Y=IPRED + W*EPS(1)
$THETA
3.72 FIX
;KGS
6.11 FIX
;NMAX
1.77 FIX
;CFU4
1.46 FIX
;KIR
0.0997 FIX ;IMAX
(80,350.27837, 1000) ;IC50
0.119 FIX
;HILL
$OMEGA
0 FIX
;0.01
;0.01
;0.5

;NMAX
;IC50
;CFU_0
;CFU4

$SIGMA
1
$EST METHOD=1 PRINT=3 MAXEVAL=9999 NSIG=2 SIGL=6 NOABORT
;$SIM (5465) ONLY SUB=1
$COV
$TABLE ID TIME DV A4 CP DRUG AMT FREQ IPRED IWRES CWRES NOPRINT
ONEHEADER FILE=sdtabXXX
$TABLE ID KGS NOPRINT ONEHEADER FILE=patabXXX
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The in vitro studies conducted to investigate the PAE potential of spectinamides
suggested that both lead and backup spectinamide exhibit strong PAE. Therefore, in the
next step of the model building process, we tried to explore the possibility of inclusion of
the PAE component in the model framework. For the practical reasons, among several
potential underlying mechanisms reported for PAE, we assumed the longer persistence of
spectinamide in subcellular components is the potential mechanism for the PAE. In the
mechanism-based PK/PD model, the concentration-time profile of spectinamide is
created by a 2-compartment PK model and the resulting concentration at any given time
is linked with the stimulatory effect on the killing of bacteria. While incorporating PAE,
we have created a hypothetical effect-compartment concentration that was identical to the
central compartment in the model until the peak concentration in each dosing interval, but
then either persisted at peak concentration for a defined time period, declined after the
peak but with a slower decline than in plasma, or a combination thereof.
The following steps were executed to perform PAE based PK/PD modeling:
1.
Obtain post hoc PK parameter estimates for each animal from the population PK
model
2.
Calculate Tmax for each animal: Equate first-order derivative expression of the
explicit equation to calculate plasma concentrations for two-compartment PK with firstorder oral absorption to zero and then perform an iterative algorithm using Microsoft
excel solver function to obtain Tmax for each animal.
3.
In NONMEM script, write explicit equations for two-compartment PK with firstorder oral absorption to generate a concentration-time profile in hypothetical PAE
compartment
4.
Link concentration of hypothetical PAE compartment to drug effect via sigmoidal
Emax function
5.
Estimate PAE either as a time period for which peak concentration persisted, or
the rate at which concentration declined after the peak but with a slower decline than in
plasma, or a combination thereof.
On the data from study 1, in the first approach, we have estimated the first-order
elimination rate constant for the decline of spectinamide concentration from the
hypothetical compartment. The NONMEM codes are provided under Model 2 and the
plot for population predicted versus observed data is shown in Figure B-2. In the second
approach, we have estimated both times for the persistence of peak concentration and
first-order elimination after peak concentration. The control stream is provided under
Model 3 and goodness of fit plots for population predicted and observed values are
depicted in Figure B-3. The inclusion of the PAE component had significantly improved
the model fit, however, both the approaches to include PAE as described above
essentially provided similar fit and comparable drop in the objective function and hence
as per the principle of parsimony we decided to move forward with the first approach
with the estimation of elimination rate constant only.
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Model 2
;; 1. Based on: 792
;; 2. Description: PAE estimation or first order rate constant-STUDY1
;; x1. Author: Santosh Wagh
$PROBLEM DYNAMIC TIMEKILL 1810
$INPUT C ID AMT TIME MDV EVID DV FREQ n DOSE CL V2 V3 Q KA Tmax
STUDY
;AMT is in mg
$DATA Lee1810_PAE_STD1.csv IGNORE=C
$SUBROUTINE ADVAN13 TOL6
$MODEL
NCOMP=4
COMP = (DEPOT,DEFDOSE)
COMP = CENTRAL
COMP = PERPIPH
;total number of of cells
COMP = Bact
;bacteria
$PK
IF (EVID.EQ.1) THEN
TDOS=TIME
TAD=0.0
ENDIF
IF (EVID.NE.1) THEN
TAD=TIME-TDOS
ENDIF
;PK MODEL
KEL = CL/V2 ; hr-1
K23 = Q/V2
K32 = Q/V3
S2 = V2
;PD MODEL
KGS = (THETA(1)/100) ;bacterial growth rate constant
NMAX = (10**THETA(2))*EXP(ETA(1))
CFU4 = (10**THETA(3));*EXP(ETA(2))
KIR = THETA(4)/1000
IMAX = THETA(5)
IC50 = THETA(6)
HILL = THETA(7)
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PAE= THETA(8)
A_0(1) = 0.0000001
A_0(4) = CFU4

$DES
TAU=FREQ
AL= 0.5*(K23+K32+KEL+SQRT((K23+K32+KEL)**2-4*K32*KEL))
BT= 0.5*(K23+K32+KEL-SQRT((K23+K32+KEL)**2-4*K32*KEL))
ST=1*DOSE*KA/V2
AM = ((K32-AL)/((KA-AL)*(BT-AL))) * ((1-EXP(-n*AL*TAU))/(1-EXP(-AL*TAU)))
BM = ((K32-BT)/((KA-BT)*(AL-BT))) * ((1-EXP(-n*BT*TAU))/(1-EXP(-BT*TAU)))
CM = ((K32-KA)/((AL-KA)*(BT-KA))) * ((1-EXP(-n*KA*TAU))/(1-EXP(KA*TAU)))
AMI=((K32-AL)/(BT-AL)) * ((1-EXP(-n*AL*TAU))/(1-EXP(-AL*TAU)))
BMI = ((K32-BT)/(AL-BT)) * ((1-EXP(-n*BT*TAU))/(1-EXP(-BT*TAU)))
AMBFI=((K32-AL)/(BT-AL)) * ((1-EXP(-(n-1)*AL*TAU))/(1-EXP(-AL*TAU)))
BMBFI = ((K32-BT)/(AL-BT)) * ((1-EXP(-(n-1)*BT*TAU))/(1-EXP(-BT*TAU)))
If (n.EQ.0) THEN
CPL=0
ELSE
CPL=ST*(AM*EXP(-AL*TAD) + BM*EXP(-BT*TAD) + CM*EXP(-KA*TAD))
ENDIF
Cmax=ST*(AM*EXP(-AL*Tmax) + BM*EXP(-BT*Tmax) + CM*EXP(-KA*Tmax))
If (CPL.LE.0) THEN
CP1=0.0001
ELSE
CP1=CPL
ENDIF
;;Calculate Cmax of the preceding dosing interval
AMBF = ((K32-AL)/((KA-AL)*(BT-AL))) * ((1-EXP(-(n-1)*AL*TAU))/(1-EXP(AL*TAU)))
BMBF = ((K32-BT)/((KA-BT)*(AL-BT))) * ((1-EXP(-(n-1)*BT*TAU))/(1-EXP(BT*TAU)))
CMBF = ((K32-KA)/((AL-KA)*(BT-KA))) * ((1-EXP(-(n-1)*KA*TAU))/(1-EXP(KA*TAU)))
If (n.LT.2) THEN
CmaxBF=0
ELSE
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CmaxBF=ST*(AMBF*EXP(-AL*Tmax) + BMBF*EXP(-BT*Tmax) + CMBF*EXP(KA*Tmax))
ENDIF
;;Calculate CBF (trough CP2 concentration of the preceding dosing interval further
decayed in the current interval)
CBF=CmaxBF*EXP(-(PAE)*(TAU+TAD-Tmax))
;;Calculate CP2
IF (TAD.LT.TMAX.AND.CP1.LT.CBF) THEN
CP2=CBF
ENDIF
IF (TAD.LT.TMAX.AND.CP1.GE.CBF) THEN
CP2=CP1
ENDIF
IF (TAD.GE.TMAX) THEN
CP2=Cmax*EXP(-(PAE)*(TAD-TMAX))
ENDIF
DADT(1) = -KA*A(1)
DADT(2) = KA*A(1) + K32*A(3) - KEL*A(2) - K23*A(2)
DADT(3) = K23*A(2) - K32*A(3)
CP = (A(2)/S2) + 0.0001
DRUG = IMAX*(CP2**HILL)/(IC50**HILL + CP2**HILL)
DADT(4) = KGS*A(4)*(1-(A(4)/NMAX)) - KIR*A(4) - DRUG*A(4)
$ERROR
A4 = A(4)
FLAG = 0
IF (F.EQ.0) FLAG = 1
IPRED=LOG10(A4)
IRES=DV-IPRED
W=1
IWRES=IRES/W
Y=IPRED + W*EPS(1)

$THETA
3.72 FIX
;KGS
6.11 FIX
;NMAX
1.77 FIX
;CFU4
1.46 FIX
;KIR
(0,0.0653 )
;IMAX
(1,100.67856);IC50
(0.1,1.023196) ;HILL
(0, 0.006754) ;PAE
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$OMEGA
0 FIX
;0.01
;0.01
;0.5

;NMAX
;IC50
;CFU_0
;CFU4

$SIGMA
0.08
$EST METHOD=1 PRINT=3 MAXEVAL=9999 NSIG=2 SIGL=6 NOABORT
;$SIM (5465) ONLY SUB=1
$COV
$TABLE ID TIME TAD CP CP2 IPRED DOSE FREQ IWRES CWRES NOPRINT
ONEHEADER FILE=sdtab793
$TABLE ID KGS NOPRINT ONEHEADER FILE=patab793

Figure B-2.

Observed vs population prediction for Model 2

Model 3
;; 1. Based on: 787
;; 2. Description:One population, PAE estimation for time for persistence of peak and
first order rate constant-STUDY1
;; x1. Author: Santosh Wagh
$PROBLEM DYNAMIC TIMEKILL 1810
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$INPUT C ID AMT TIME MDV EVID DV FREQ n DOSE CL V2 V3 Q KA Tmax
STUDY
;AMT is in mg
$DATA Lee1810_PAE_STD1.csv IGNORE=C
$SUBROUTINE ADVAN13 TOL6
$MODEL
NCOMP=4
COMP = (DEPOT,DEFDOSE)
COMP = CENTRAL
COMP = PERPIPH
;total number of of cells
COMP = Bact
;bacteria
$PK
IF (EVID.EQ.1) THEN
TDOS=TIME
TAD=0.0
ENDIF
IF (EVID.NE.1) THEN
TAD=TIME-TDOS
ENDIF
;PK MODEL
KEL = CL/V2 ; hr-1
K23 = Q/V2
K32 = Q/V3
S2 = V2
;PD MODEL
KGS = (THETA(1)/100) ;bacterial growth rate constant
NMAX = (10**THETA(2))*EXP(ETA(1))
CFU4 = (10**THETA(3));*EXP(ETA(2))
KIR = THETA(4)/1000
IMAX = THETA(5)
IC50 = THETA(6)
HILL = THETA(7)
PAET= THETA(8)
PAER= THETA(9)
A_0(1) = 0.0000001
A_0(4) = CFU4
$DES
TAU=FREQ
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AL= 0.5*(K23+K32+KEL+SQRT((K23+K32+KEL)**2-4*K32*KEL))
BT= 0.5*(K23+K32+KEL-SQRT((K23+K32+KEL)**2-4*K32*KEL))
ST=1*DOSE*KA/V2
AM = ((K32-AL)/((KA-AL)*(BT-AL))) * ((1-EXP(-n*AL*TAU))/(1-EXP(-AL*TAU)))
BM = ((K32-BT)/((KA-BT)*(AL-BT))) * ((1-EXP(-n*BT*TAU))/(1-EXP(-BT*TAU)))
CM = ((K32-KA)/((AL-KA)*(BT-KA))) * ((1-EXP(-n*KA*TAU))/(1-EXP(KA*TAU)))
AMI=((K32-AL)/(BT-AL)) * ((1-EXP(-n*AL*TAU))/(1-EXP(-AL*TAU)))
BMI = ((K32-BT)/(AL-BT)) * ((1-EXP(-n*BT*TAU))/(1-EXP(-BT*TAU)))
AMBFI=((K32-AL)/(BT-AL)) * ((1-EXP(-(n-1)*AL*TAU))/(1-EXP(-AL*TAU)))
BMBFI = ((K32-BT)/(AL-BT)) * ((1-EXP(-(n-1)*BT*TAU))/(1-EXP(-BT*TAU)))
If (n.EQ.0) THEN
CPL=0
ELSE
CPL=ST*(AM*EXP(-AL*TAD) + BM*EXP(-BT*TAD) + CM*EXP(-KA*TAD))
ENDIF
Cmax=ST*(AM*EXP(-AL*Tmax) + BM*EXP(-BT*Tmax) + CM*EXP(-KA*Tmax))
If (CPL.LE.0) THEN
CP1=0.0001
ELSE
CP1=CPL
ENDIF
;;Calculate Cmax of the preceding dosing interval
AMBF = ((K32-AL)/((KA-AL)*(BT-AL))) * ((1-EXP(-(n-1)*AL*TAU))/(1-EXP(AL*TAU)))
BMBF = ((K32-BT)/((KA-BT)*(AL-BT))) * ((1-EXP(-(n-1)*BT*TAU))/(1-EXP(BT*TAU)))
CMBF = ((K32-KA)/((AL-KA)*(BT-KA))) * ((1-EXP(-(n-1)*KA*TAU))/(1-EXP(KA*TAU)))
If (n.LT.2) THEN
CmaxBF=0
ELSE
CmaxBF=ST*(AMBF*EXP(-AL*Tmax) + BMBF*EXP(-BT*Tmax) + CMBF*EXP(KA*Tmax))
ENDIF
;;Calculate CBF (trough CP2 concentration of the preceding dosing interval further
decayed in the current interval)
TSUM=TAU+TAD-(Tmax+PAET)
IF (TSUM.LE.0) THEN
CBF=CmaxBF
ELSE
CBF=CmaxBF*EXP(-PAER*(TAU+TAD-(Tmax+PAET)))
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ENDIF
;;Calculate CP2
IF (TAD.LT.TMAX.AND.CP1.LT.CBF) THEN
CP2=CBF
ENDIF
IF (TAD.LT.TMAX.AND.CP1.GE.CBF) THEN
CP2=CP1
ENDIF
IF (TAD.GE.Tmax.AND.TAD.LT.(Tmax+PAET)) THEN
CP2=Cmax
ENDIF
IF (TAD.GE.(Tmax+PAET)) THEN
CP2=Cmax*EXP(-PAER*(TAD-(Tmax+PAET)))
ENDIF
DADT(1) = -KA*A(1)
DADT(2) = KA*A(1) + K32*A(3) - KEL*A(2) - K23*A(2)
DADT(3) = K23*A(2) - K32*A(3)
CP = (A(2)/S2) + 0.0001
DRUG = IMAX*(CP2**HILL)/(IC50**HILL + CP2**HILL)
DADT(4) = KGS*A(4)*(1-(A(4)/NMAX)) - KIR*A(4) - DRUG*A(4)
$ERROR
A4 = A(4)
FLAG = 0
IF (F.EQ.0) FLAG = 1
IPRED=LOG10(A4)
IRES=DV-IPRED
W=1
IWRES=IRES/W
Y=IPRED + W*EPS(1)
$THETA
3.72 FIX
;KGS
6.11 FIX
;NMAX
1.77 FIX
;CFU4
1.46 FIX
;KIR
(0,0.0653 )
;IMAX
(1,450.67856);IC50
(0.1,1.023196) ;HILL
(0, 60.3457) ;PAET
(0, 0.02368) ;PAER
$OMEGA
0 FIX

;NMAX

79

;0.01
;0.01
;0.5

;IC50
;CFU_0
;CFU4

$SIGMA
0.08
$EST METHOD=1 PRINT=3 MAXEVAL=9999 NSIG=2 SIGL=6 NOABORT
;$SIM (5465) ONLY SUB=1
$COV
$TABLE ID TIME TAD CP CP2 IPRED DOSE FREQ IWRES CWRES NOPRINT
ONEHEADER FILE=sdtab802
$TABLE ID KGS NOPRINT ONEHEADER FILE=patab802

Figure B-3.

Observed vs population prediction for Model 3

After analyzing study 1 data with Model 3, we have appended the data from study
2 and analyzed the combined data using Model 3. For further refinement, we decided to
address study-specific differences. To address study-specific differences, we applied
study as a covariate on fixed and random effect parameters. The study covariate on fixed
effect and random effect parameters was defined as shown in Equation B-1 and B-2,
respectively.
𝑃 = Θ1 ∙ (Θ2 )𝑆𝑇𝑈𝐷𝑌

Eq. B-1

Where P represents the typical value of the parameter in the population, STUDY
is an indicator variable equal to 0 for study 1 and 1 for study 2, Θ1 is the typical value of
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P for study 1, and Θ2 is the multiplicative factor describing the increase or decrease in P
in study 2.
𝑌 = 𝐼𝑃𝑅𝐸𝐷 + 𝑊 ∗ 𝐸𝑃𝑆(1) ∗ (1 − 𝑆𝑇𝑈𝐷𝑌) + 𝑊 ∗ 𝐸𝑃𝑆(2) ∗ 𝑆𝑇𝑈𝐷𝑌

Eq. B-2

Where Y represents population prediction, IPRED represents individual
prediction, EPS 1 and EPS 2 are random unexplained variability for study 1 and study 2
respectively, STUDY is an indicator variable equal to 0 for study 1 and 1 for study 2.
After evaluating study-specific differences on fixed and random effect
parameters, the study effect on both the fixed-effect parameter, Emax, and random
variability was significant and provided the best fit. The NONMEM code for the final
mechanism-based PK/PD model is provided under Model 4 and the goodness of fit plot
for population prediction versus observed values is shown in Figure B-4.
Model 4
;; 1. Based on: 817
;; 2. Description: One population, PAE estimation for time for the persistence of peak and
first order rate constant-STUDY1&2-study covariate on Emax and EPS
;; x1. Author: Santosh Wagh
$PROBLEM DYNAMIC TIMEKILL 1810
$INPUT C ID AMT TIME MDV EVID DV FREQ n DOSE CL V2 V3 Q KA Tmax
STUDY
;AMT is in mg
$DATA Lee1810_PAE_MS2.csv IGNORE=C
$SUBROUTINE ADVAN13 TOL6
$MODEL
NCOMP=4
COMP = (DEPOT,DEFDOSE)
COMP = CENTRAL
COMP = PERPIPH
;total number of of cells
COMP = Bact
;bacteria
$PK
IF (EVID.EQ.1) THEN
TDOS=TIME
TAD=0.0
ENDIF
IF (EVID.NE.1) THEN
TAD=TIME-TDOS
ENDIF
;PK MODEL
KEL = CL/V2 ; hr-1
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K23 = Q/V2
K32 = Q/V3
S2 = V2
;PD MODEL
KGS = (THETA(1)/100) ;bacterial growth rate constant
NMAX = (10**THETA(2))*EXP(ETA(1))
CFU4 = (10**THETA(3));*EXP(ETA(2))
KIR = THETA(4)/1000
IMAX = THETA(5)*THETA(9)**STUDY
IC50 = THETA(6)
HILL = THETA(7)
PAE= THETA(8)
A_0(1) = 0.0000001
A_0(4) = CFU4
$DES
TAU=FREQ
AL= 0.5*(K23+K32+KEL+SQRT((K23+K32+KEL)**2-4*K32*KEL))
BT= 0.5*(K23+K32+KEL-SQRT((K23+K32+KEL)**2-4*K32*KEL))
ST=1*DOSE*KA/V2
AM = ((K32-AL)/((KA-AL)*(BT-AL))) * ((1-EXP(-n*AL*TAU))/(1-EXP(-AL*TAU)))
BM = ((K32-BT)/((KA-BT)*(AL-BT))) * ((1-EXP(-n*BT*TAU))/(1-EXP(-BT*TAU)))
CM = ((K32-KA)/((AL-KA)*(BT-KA))) * ((1-EXP(-n*KA*TAU))/(1-EXP(KA*TAU)))
AMI=((K32-AL)/(BT-AL)) * ((1-EXP(-n*AL*TAU))/(1-EXP(-AL*TAU)))
BMI = ((K32-BT)/(AL-BT)) * ((1-EXP(-n*BT*TAU))/(1-EXP(-BT*TAU)))
AMBFI=((K32-AL)/(BT-AL)) * ((1-EXP(-(n-1)*AL*TAU))/(1-EXP(-AL*TAU)))
BMBFI = ((K32-BT)/(AL-BT)) * ((1-EXP(-(n-1)*BT*TAU))/(1-EXP(-BT*TAU)))
If (n.EQ.0) THEN
CPL=0
ELSE
CPL=ST*(AM*EXP(-AL*TAD) + BM*EXP(-BT*TAD) + CM*EXP(-KA*TAD))
ENDIF
Cmax=ST*(AM*EXP(-AL*Tmax) + BM*EXP(-BT*Tmax) + CM*EXP(-KA*Tmax))
If (CPL.LE.0) THEN
CP1=0.0001
ELSE
CP1=CPL
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ENDIF
;;Calculate Cmax of the preceding dosing interval
AMBF = ((K32-AL)/((KA-AL)*(BT-AL))) * ((1-EXP(-(n-1)*AL*TAU))/(1-EXP(AL*TAU)))
BMBF = ((K32-BT)/((KA-BT)*(AL-BT))) * ((1-EXP(-(n-1)*BT*TAU))/(1-EXP(BT*TAU)))
CMBF = ((K32-KA)/((AL-KA)*(BT-KA))) * ((1-EXP(-(n-1)*KA*TAU))/(1-EXP(KA*TAU)))
If (n.LT.2) THEN
CmaxBF=0
ELSE
CmaxBF=ST*(AMBF*EXP(-AL*Tmax) + BMBF*EXP(-BT*Tmax) + CMBF*EXP(KA*Tmax))
ENDIF
;;Calculate CBF (trough CP2 concentration of the preceding dosing interval further
decayed in the current interval)
CBF=CmaxBF*EXP(-(PAE)*(TAU+TAD-Tmax))
;;Calculate CP2
IF (TAD.LT.TMAX.AND.CP1.LT.CBF) THEN
CP2=CBF
ENDIF
IF (TAD.LT.TMAX.AND.CP1.GE.CBF) THEN
CP2=CP1
ENDIF
IF (TAD.GE.TMAX) THEN
CP2=Cmax*EXP(-(PAE)*(TAD-TMAX))
ENDIF
DADT(1) = -KA*A(1)
DADT(2) = KA*A(1) + K32*A(3) - KEL*A(2) - K23*A(2)
DADT(3) = K23*A(2) - K32*A(3)
CP = (A(2)/S2) + 0.0001
DRUG = IMAX*(CP2**HILL)/(IC50**HILL + CP2**HILL)
DADT(4) = KGS*A(4)*(1-(A(4)/NMAX)) - KIR*A(4) - DRUG*A(4)
$ERROR
A4 = A(4)
FLAG = 0
IF (F.EQ.0) FLAG = 1
IPRED=LOG10(A4)
IRES=DV-IPRED
W=1
IWRES=IRES/W
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Y=IPRED + W*EPS(1)*(1-STUDY) + W*EPS(2)*STUDY
$THETA
3.72 FIX
;KGS
6.11 FIX
;NMAX
1.77 FIX
;CFU4
1.46 FIX
;KIR
(0,0.0653 )
;IMAX
(1,400.67856);IC50
(0.1,1.023196) ;HILL
(0, 0.01754) ;PAE
(0, 1.52335) ;Imax study
$OMEGA
0 FIX
;0.01
;0.01
;0.5

;NMAX
;IC50
;CFU_0
;CFU4

$SIGMA
0.08
0.08
$EST METHOD=1 PRINT=3 MAXEVAL=9999 NSIG=2 SIGL=6 NOABORT
;$SIM (5465) ONLY SUB=1
$COV
$TABLE ID TIME TAD CP CP2 IPRED DOSE FREQ IWRES CWRES NOPRINT
ONEHEADER FILE=sdtab818
$TABLE ID KGS NOPRINT ONEHEADER FILE=patab818
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Figure B-4.

Observed vs population prediction for Model 4
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